

*Expenditure
and
Prescriptions
Twelve Months
to
30 June
2018*

***PBS Information Management Section
Pricing and PBS Policy Branch
Technology Assessment and Access Division***

This publication and previous editions can be accessed via the internet:
<http://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries about this publication or requests for complimentary copies via:

Surface mail: Director
PBS Information Management Section
Pricing and PBS Policy Branch, MDP 900
Department of Health
GPO Box 9848 Canberra ACT 2601

E-mail: pbsstats@health.gov.au

Important Information

Unless otherwise indicated this publication has been produced using data provided to the Department of Health by the Department of Human Services. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by the Department of Human Services. They refer only to paid services processed for prescriptions submitted and claimed via the PBS Online claiming system by the approved suppliers. They do not include any manually paid claims.

PBS Expenditure includes the following patient categories:

- General - Non-Safety Net (Ordinary)
- General - Safety Net
- Concessional - Non-Safety Net (Ordinary)
- Concessional - Safety Net
- Doctor's Bag

The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:

- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card

There are two safety net thresholds – one for General patients and the other for Concessional patients.

From 1 January 2018, the general patient safety net threshold was **\$1,521.80**. When patients and/or their families reached this amount, they could apply for a Safety Net Card and pay only **\$6.40** per prescription for the rest of the calendar year. The concessional safety net threshold was **\$384.00**. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.

The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.

Caution should be exercised in referring to the breakdown by patient category in Table 21(a) on pages 26 to 27 and Table 21(b) on pages 28 to 31, because of a past problem in data supplied by the Department of Human Services whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem was fixed for 2008-09, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

While Section 100 data has been included in the majority of tables for the first time in this report, this data does not include supplies to Aboriginal Health Services.

The Department of Health has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

Summary of Pharmaceutical Benefits Scheme 2017-2018

Total Pharmaceutical Benefits Scheme (PBS) government expenditure (both Section 85 and Section 100) on an accrual accounting basis for the 2017-2018 financial year was **\$11,690 million** (excluding revenue), compared with **\$12,058 million** for the previous year. This is a decrease of **3.0%**.

The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by date of supply financial year, however a few tables refer to Section 85 only and there are some tables that report pharmacy program expenditure.

Total 2017-18 PBS subsidised prescription volumes increased by **0.8%** to a total of **204.1 million**, compared to 202.4 million for the 2016-17 financial year.

In 2017-18, PBS Government expenditure (Section 85 and Section 100) was **\$11,602.9 million** (excluding rebates) which is **88.9%** of the total cost of PBS prescriptions. The remainder was patient contributions that amounted to **\$1,455.5 million**.

The majority of government expenditure in 2017-18 on PBS Section 85 and Section 100 prescriptions was directed towards concessional cardholders (**\$7,866.1 million, 67.8% of the total**), compared to concessional cardholders expenditure for 2016-17 (**\$8,121.4 million, 67.9%** of the total).

The average dispensed price (Patient payment plus Government benefit) per prescription of PBS subsidised medicines decreased to \$64.04 in 2017-18, compared to \$66.09 in 2016-17.

Note: From 2016-17 this publication is based on the date that a prescription medicine was supplied to a patient. Previous publications were based on the date that a claim was processed (and the payment finalised) by the Department of Human Services. The historical data from 1948-49 to 2015-16 on pages 26 to 31 remains by date of processing.

List of tables

Table	Description	Page
Table 1(a)	PBS Expenditure on Accrual Accounting Basis, 2016-17 and 2017-18	1
Table 1(b)	PBS Section 100 Programmes on Accrual Accounting Basis, 2016-17 and 2017-18	1
Table 2(a)	PBS Prescriptions, 2016-17 and 2017-18 (incl. under co-pay prescriptions)	2
Table 2(b)	PBS Government Cost, 2016-17 and 2017-18 (excl. under co-pay prescriptions)	2
Table 2(c)	RPBS and PBS Subsidised Prescriptions for DVA patients, 2016-17 and 2017-18 (excl. under co-pay prescriptions)	2
Table 2(d)	RPBS and PBS Government Cost for DVA patients, 2016-17 and 2017-18 (excl. under co-pay prescriptions)	2
Table 3(a)	PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2017-18 (excl. under co-pay prescriptions)	3
Table 3(b)	PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2017-18 (excl. under co-pay prescriptions)	3
Table 3(c)	PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2016-17 and 2017-18 (excl. under co-pay prescriptions)	3
Table 4	PBS Subsidised Prescriptions by Pharmacy State, 2017-18 (excl. under co-pay prescriptions)	4
Table 5(a)	Top 50 PBS Drugs (Generic Name) Sorted by Highest Government Cost, 2017-18 (excl. under co-pay prescriptions)	5
Table 5(b)	Top 50 PBS Drugs (Generic Name) Sorted by Highest Subsidised Prescriptions, 2017-18 (excl. under co-pay prescriptions)	6
Table 6	Top 50 PBS Drugs (Generic Name) Sorted by Highest Total Prescription Volume, 2017-18 (incl. under co-pay prescriptions)	7
Table 7	Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2017-18 (incl. under co-pay prescriptions)	8
Table 8	ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2016-17 and 2017-18 (excl. under co-pay prescriptions)	9
Table 9(a)	Top 35 Drugs Sorted by Highest Change to Government Cost, 2016-17 and 2017-18 (excl. under co-pay prescriptions)	10
Table 9(b)	Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2016-17 and 2017-18 (excl. under co-pay prescription)	11
Table 10(a)	PBS Section 85 Prescription Volume, 2014-15 to 2017-18 (incl. under co-pay prescriptions, Section 85 only)	12
Table 10(b)	PBS Section 85 expenditure, 2014-15 to 2017-18 (excl. under co-pay prescriptions, Section 85 only)	12
Table 11	PBS Prescriptions and Government Cost by Formulary, 2017-18 (incl. under co-pay prescriptions)	13

Table 12(a)	Top 20 Responsible Persons by Total Cost, 2017-18 (incl. under co-pay prescriptions)	14
Table 12(b)	Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2017-18 (incl. under co-pay prescriptions)	15
Table 12(c)	Top 20 Responsible Persons by Total PBS Prescriptions, 2017-18 (incl. under co-pay prescriptions)	16
Table 13	Number of PBS Approved Suppliers, 30 June 2018	17
Table 14	PBS Brand Premiums, 2017-18	17
Table 15(a)	PBS/RPBS prescriptions dispensed by Community Pharmacies, 2017-18	18
Table 15(b)	PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2017-18	18
Table 16(a)	PBS/RPBS Continued Dispensing Medicines Prescriptions by Dispensing Pharmacy State, 2017-18 (incl. under co-pay prescriptions)	19
Table 16(b)	PBS/RPBS Continued Dispensing Medicines Government Cost by Dispensing Pharmacy State, 2017-18 (incl. under co-pay prescriptions)	19
Supplement 1	Community Pharmacy Agreement (CPA) Expenses	
Table 17	Remuneration for Community Pharmacies and Friendly Societies, 2017-18 (excl. under co-pay prescriptions)	20
Table 18	CPA Professional Pharmacy Programmes Expenditure, 2017-18	21
Table 19	Actual Costs of Major Components of CPA, 2017-18	22
Table 20	Community Services Obligation (CSO) Expenditure, 2017-18	22
Supplement 2	PBS Information Line Report, 2017-18	23
Supplement 3	National Diabetes Services Scheme (NDSS)	24
Supplement 4	Historical PBS Prescriptions and Expenditure	
Table 21(a)	Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2017-18)	26
Table 21(b)	Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2017-18)	28

Table 1(a): PBS Expenditure on Accrual Accounting Basis, 2016-17 and 2017-18

Category	2016-17	Percentage of Total	2017-18	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$ 6,716,569,270	55.7%	\$ 6,204,796,316	53.1%	-\$ 511,772,954	-7.6%
Section 85 - General	\$ 2,176,675,514	18.1%	\$ 1,834,103,627	15.7%	-\$ 342,571,887	-15.7%
Doctors' Bag	\$ 18,906,365	0.2%	\$ 18,205,147	0.2%	-\$ 701,218	-3.7%
Section 100*	\$ 3,135,750,822	26.0%	\$ 3,622,593,041	31.0%	\$ 486,842,219	15.5%
Safety Net Cards	\$ 9,721,956	0.1%	\$ 10,525,652	0.1%	\$ 803,696	8.3%
Total	\$ 12,057,623,927	100.0%	\$ 11,690,223,783	100.0%	-\$ 367,400,144	-3.0%
Total Including Revenue**	\$ 8,790,109,229		\$ 9,331,360,544		\$ 541,251,315	6.2%

*Individual S100 programmes are shown in Table 1(b).

**The basis for reporting PBS revenue has changed between 2015-16 and 2016-17, and this means that Total Including Revenue cannot be compared between 2015-16 and later years. The change in reporting PBS Revenue in 2016-17 brings this report into line with PBS revenue as reported in the Department of Health Annual Report.

Table 1(b): PBS Section 100 Programmes on Accrual Accounting Basis, 2016-17 and 2017-18

Category	2016-17	Percentage of Total	2017-18	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs	\$ 1,910,193,161	60.9%	\$ 1,820,964,882	50.3%	-\$ 89,228,279	-4.7%
Chemotherapy (EFC & CPAP)^	\$ 946,706,306	25.4%	\$ 1,514,452,319	41.8%	\$ 567,746,013	60.0%
In Vitro Fertilisation	\$ 116,331,471	3.7%	\$ 108,511,462	3.0%	-\$ 7,820,009	-6.7%
Opiate Dependence Treatment Program	\$ 51,560,961	1.6%	\$ 56,249,840	1.6%	\$ 4,688,879	9.1%
Aboriginal Health Services (GST exclusive)	\$ 42,642,523	1.4%	\$ 44,087,205	1.2%	\$ 1,444,681	3.4%
Botulinum Toxin Program (incl. Dysport)	\$ 42,235,114	1.3%	\$ 50,961,818	1.4%	\$ 8,726,704	20.7%
Human Growth Hormones	\$ 25,503,407	0.8%	\$ 26,844,849	0.7%	\$ 1,341,441	5.3%
Paraplegic and Quadriplegic Program	\$ 390,102	0.0%	\$ 360,357	0.0%	-\$ 29,745	-7.6%
Continuing Medication Program	\$ 187,776	0.0%	\$ 160,310	0.0%	-\$ 27,466	-14.6%
Total	\$ 3,135,750,822	100.0%	\$ 3,622,593,041	100.0%	\$ 486,842,219	15.5%

Note:

Expenditure figures refer to payments made through the Department of Human Services and directly from the Department of Health Financial Journaling System.

This data reflects the current definitions of Section 100 programs as published on www.pbs.gov.au.

^Chemotherapy (EFC & CPAP) includes expenditure for medicines previously provided through the Special Authority Program.

Table 2(a): PBS Prescriptions, 2016-17 and 2017-18

Section 85 and S100*, including Drs Bag and under co-payment prescriptions

Patient Category	2016-17		2017-18		PBS Prescriptions Change	PBS Prescriptions Change Percentage
	PBS Prescriptions	Percentage	PBS Prescriptions	Percentage		
Concessional Non-Safety Net	148,455,821	73.4%	149,298,882	73.2%	843,061	0.6%
Concessional Safety Net	36,967,542	18.3%	37,145,360	18.2%	177,818	0.5%
Total Concessional	185,423,363	91.6%	186,444,242	91.4%	1,020,879	0.6%
General Non-Safety Net	13,747,993	6.8%	14,579,026	7.1%	831,033	6.0%
General Safety Net	2,791,922	1.4%	2,638,328	1.3%	-153,594	-5.5%
Total General	16,539,915	8.2%	17,217,354	8.4%	677,439	4.1%
Doctors Bag	404,878	0.2%	398,051	0.2%	-6,827	-1.7%
Total (Over Co-payment)	202,368,156	100.0%	204,059,647	100.0%	1,691,491	0.8%
Under Co-payment	86,267,505		89,494,710		3,227,205	3.7%

Table 2(b): PBS Government Cost, 2016-17 and 2017-18

Section 85 and S100*, including Drs Bag and excluding under co-payment prescriptions

Patient Category	2016-17		2017-18		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Concessional Non-Safety Net	\$ 6,786,914,403	56.7%	\$ 6,523,560,637	56.2%	-\$ 263,353,766	-3.9%
Concessional Safety Net	\$ 1,334,504,917	11.2%	\$ 1,342,578,304	11.6%	\$ 8,073,387	0.6%
Total Concessional	\$ 8,121,419,320	67.9%	\$ 7,866,138,941	67.8%	-\$ 255,280,379	-3.1%
General Non-Safety Net	\$ 3,694,171,893	30.9%	\$ 3,599,666,568	31.0%	-\$ 94,505,325	-2.6%
General Safety Net	\$ 127,013,410	1.1%	\$ 120,489,800	1.0%	-\$ 6,523,610	-5.1%
Total General	\$ 3,821,185,304	32.0%	\$ 3,720,156,368	32.1%	-\$ 101,028,936	-2.6%
Doctors Bag	\$ 17,157,705	0.1%	\$ 16,568,617	0.1%	-\$ 589,088	-3.4%
Total (Over Co-payment)	\$ 11,959,762,329	100.0%	\$ 11,602,863,926	100.0%	-\$ 356,898,402	-3.0%

Table 2(c): RPBS and PBS Subsidised Prescriptions for DVA patients, 2016-17 and 2017-18

PBS Section 85 and S100* and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2016-17		2017-18		Subsidised Prescriptions Change	Subsidised Prescriptions Change Percentage
	Subsidised Prescriptions	Percentage	Subsidised Prescriptions	Percentage		
Repatriation Non-Safety Net	7,121,415	75%	6,730,178	75%	-391,237	-5.5%
Repatriation Safety Net	2,409,644	25%	2,257,260	25%	-152,384	-6.3%
Total Repatriation	9,531,059	100%	8,987,438	100%	-543,621	-5.7%

Table 2(d): RPBS and PBS Government Cost for DVA patients, 2016-17 and 2017-18

Section 85 and S100* and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	2016-17		2017-18		Government Cost Change	Government Cost Change Percentage
	Government Cost	Percentage	Government Cost	Percentage		
Repatriation Non-Safety Net	\$ 245,601,119	76%	\$ 250,768,574	77%	\$ 5,167,455	2.1%
Repatriation Safety Net	\$ 76,723,475	24%	\$ 72,975,423	23%	-\$ 3,748,052	-4.9%
Total Repatriation	\$ 322,324,594	100%	\$ 323,743,997	100%	\$ 1,419,403	0.4%

* Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 3(a): PBS Section 85 Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2017-18

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2017-18	Concessional Non-Safety Net	148,018,925	\$ 5,127,198,161	\$ 915,055,636	\$ 6,042,253,797	\$ 40.82
	Concessional Safety Net	37,047,645	\$ 1,236,961,876	\$ -	\$ 1,236,961,876	\$ 33.39
	Total Concessional	185,066,570	\$ 6,364,160,037	\$ 915,055,636	\$ 7,279,215,673	\$ 39.33
	General Non-Safety Net	13,332,423	\$ 1,981,594,072	\$ 484,120,874	\$ 2,465,714,946	\$ 184.94
	General Safety Net	2,616,813	\$ 101,429,150	\$ 16,143,997	\$ 117,573,148	\$ 44.93
	Total General	15,949,236	\$ 2,083,023,223	\$ 500,264,871	\$ 2,583,288,094	\$ 161.97
	Total (excluding Drs Bag)	201,015,806	\$ 8,447,183,260	\$ 1,415,320,507	\$ 9,862,503,767	\$ 49.06
	Doctors Bag	398,051	\$ 16,568,617	\$ -	\$ 16,568,617	\$ 41.62
Total (including Drs Bag)	201,413,857	\$ 8,463,751,877	\$ 1,415,320,507	\$ 9,879,072,384	\$ 49.05	

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(b): PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2017-18

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
2017-18	Concessional Non-Safety Net	149,298,882	\$ 6,523,560,637	\$ 920,769,299	\$ 7,444,329,935	\$ 49.86
	Concessional Safety Net	37,145,360	\$ 1,342,578,304	\$ -	\$ 1,342,578,304	\$ 36.14
	Total Concessional	186,444,242	\$ 7,866,138,941	\$ 920,769,299	\$ 8,786,908,240	\$ 47.13
	General Non-Safety Net	14,579,026	\$ 3,599,666,568	\$ 518,490,769	\$ 4,118,157,337	\$ 282.47
	General Safety Net	2,638,328	\$ 120,489,800	\$ 16,243,574	\$ 136,733,374	\$ 51.83
	Total General	17,217,354	\$ 3,720,156,368	\$ 534,734,343	\$ 4,254,890,711	\$ 247.13
	Total (excluding Drs Bag)	203,661,596	\$ 11,586,295,309	\$ 1,455,503,642	\$ 13,041,798,951	\$ 64.04
	Doctors Bag	398,051	\$ 16,568,617	\$ -	\$ 16,568,617	\$ 41.62
Total (including Drs Bag)	204,059,647	\$ 11,602,863,926	\$ 1,455,503,642	\$ 13,058,367,568	\$ 63.99	

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 3(c): PBS Prescriptions, Government Cost, Patient Contribution and Average Price by Month of Supply, 2016-17 and 2017-18

Section 85 and Section 100, excluding Drs Bag and including under co-payment prescriptions

Year	Month	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only)***	Total Cost*	Ave. Price**
2016	Jul	16,540,319	7,244,023	23,784,342	\$ 1,086,070,703	\$ 117,218,104	\$ 1,203,288,807	\$ 72.75
	Aug	17,693,107	7,694,146	25,387,253	\$ 1,143,902,723	\$ 117,354,536	\$ 1,261,257,258	\$ 71.29
	Sep	17,170,565	7,172,514	24,343,079	\$ 1,074,260,028	\$ 106,343,073	\$ 1,180,603,101	\$ 68.76
	Oct	17,163,784	7,018,005	24,181,789	\$ 1,021,742,393	\$ 99,022,878	\$ 1,120,765,271	\$ 65.30
	Nov	17,905,282	6,900,655	24,805,937	\$ 1,062,887,002	\$ 96,816,284	\$ 1,159,703,286	\$ 64.77
	Dec	20,088,442	6,908,727	26,997,169	\$ 1,097,754,263	\$ 95,750,064	\$ 1,193,504,327	\$ 59.41
2017	Jan	14,292,795	6,789,675	21,082,470	\$ 851,395,328	\$ 119,477,908	\$ 970,873,236	\$ 67.93
	Feb	14,678,834	6,666,466	21,345,300	\$ 855,269,267	\$ 121,817,171	\$ 977,086,438	\$ 66.56
	Mar	16,844,454	7,532,657	24,377,111	\$ 994,930,902	\$ 139,121,004	\$ 1,134,051,906	\$ 67.32
	Apr	15,298,513	6,984,700	22,283,213	\$ 837,393,033	\$ 125,417,533	\$ 962,810,566	\$ 62.93
	May	17,457,150	7,794,651	25,251,801	\$ 980,671,328	\$ 138,639,752	\$ 1,119,311,080	\$ 64.12
	Jun	16,830,033	7,561,248	24,391,281	\$ 936,327,654	\$ 127,893,312	\$ 1,064,220,965	\$ 63.23
Total		201,963,278	86,267,467	288,230,745	\$ 11,942,604,623	\$ 1,404,871,618	\$ 13,347,476,242	\$ 66.09
2017	Jul	16,830,143	7,634,282	24,464,425	\$ 940,008,463	\$ 121,753,410	\$ 1,061,761,873	\$ 63.09
	Aug	17,887,748	7,977,793	25,865,541	\$ 1,029,911,096	\$ 120,988,988	\$ 1,150,900,084	\$ 64.34
	Sep	16,996,996	7,391,560	24,388,556	\$ 974,403,010	\$ 107,699,712	\$ 1,082,102,722	\$ 63.66
	Oct	17,610,515	7,257,385	24,867,900	\$ 1,014,245,864	\$ 104,492,049	\$ 1,118,737,913	\$ 63.53
	Nov	18,010,343	7,037,249	25,047,592	\$ 1,039,662,989	\$ 100,095,599	\$ 1,139,758,587	\$ 63.28
	Dec	19,552,790	7,006,046	26,558,836	\$ 1,057,744,382	\$ 96,330,703	\$ 1,154,075,085	\$ 59.02
2018	Jan	14,986,302	7,201,551	22,187,853	\$ 884,011,433	\$ 128,121,720	\$ 1,012,133,153	\$ 67.54
	Feb	14,883,720	6,922,872	21,806,592	\$ 858,362,209	\$ 126,702,812	\$ 985,065,021	\$ 66.18
	Mar	16,699,045	7,791,215	24,490,260	\$ 952,656,575	\$ 141,895,024	\$ 1,094,551,599	\$ 65.55
	Apr	15,933,658	7,413,543	23,347,201	\$ 892,840,848	\$ 134,020,191	\$ 1,026,861,040	\$ 64.45
	May	17,729,679	8,054,147	25,783,826	\$ 1,031,915,043	\$ 145,134,935	\$ 1,177,049,978	\$ 66.39
	Jun	16,540,657	7,807,062	24,347,719	\$ 910,533,399	\$ 128,268,497	\$ 1,038,801,896	\$ 62.80
Total		203,661,596	89,494,705	293,156,301	\$ 11,586,295,309	\$ 1,455,503,642	\$ 13,041,798,951	\$ 64.04

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution reported in table 3(b) in the 2016-17 report included under co-payment prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 4: PBS Subsidised Prescriptions by Pharmacy State, 2017-18

Section 85 and Section 100[^], excluding Drs Bag and excluding under co-payment prescriptions

PBS S85 subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	48,467,404	37,419,737	30,097,413	12,569,035	13,137,939	4,277,413	531,361	1,518,623	148,018,925
Concessional Safety Net	13,075,236	9,131,783	7,310,026	3,091,725	2,967,065	1,063,052	55,972	352,786	37,047,645
General Non-Safety Net	4,397,558	3,107,806	2,739,808	897,359	1,489,893	290,621	125,909	283,469	13,332,423
General Safety Net	927,252	627,800	463,799	188,548	284,171	48,657	7,603	68,983	2,616,813
Total	66,867,450	50,287,126	40,611,046	16,746,667	17,879,068	5,679,743	720,845	2,223,861	201,015,806
PBS (S85 + S100) subsidised prescriptions	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	48,863,637	37,751,838	30,364,398	12,664,987	13,259,223	4,307,588	541,559	1,545,652	149,298,882
Concessional Safety Net	13,102,012	9,161,994	7,331,154	3,099,137	2,975,526	1,065,333	56,125	354,079	37,145,360
General Non-Safety Net	4,811,894	3,421,446	2,961,631	978,194	1,619,175	311,678	138,628	336,380	14,579,026
General Safety Net	931,534	635,290	469,571	189,502	286,487	48,902	7,609	69,433	2,638,328
Total	67,709,077	50,970,568	41,126,754	16,931,820	18,140,411	5,733,501	743,921	2,305,544	203,661,596
Government Cost (S85 only)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 1,687,020,304	\$ 1,288,394,162	\$ 1,057,652,025	\$ 414,095,661	\$ 453,017,129	\$ 151,637,597	\$ 17,069,531	\$ 58,311,752	\$ 5,127,198,161
Concessional Safety Net	\$ 434,004,977	\$ 303,186,757	\$ 245,196,006	\$ 102,549,289	\$ 101,151,244	\$ 36,338,325	\$ 1,816,076	\$ 12,719,202	\$ 1,236,961,876
General Non-Safety Net	\$ 624,848,260	\$ 523,045,803	\$ 373,855,762	\$ 130,415,205	\$ 227,208,105	\$ 46,616,749	\$ 14,498,737	\$ 41,105,451	\$ 1,981,594,072
General Safety Net	\$ 35,581,199	\$ 24,160,667	\$ 17,134,420	\$ 7,483,051	\$ 12,138,575	\$ 1,873,497	\$ 286,858	\$ 2,770,883	\$ 101,429,150
Total	\$ 2,781,454,741	\$ 2,138,787,389	\$ 1,693,838,213	\$ 654,543,206	\$ 793,515,054	\$ 236,466,168	\$ 33,671,202	\$ 114,907,288	\$ 8,447,183,260
Government Cost (S85+ S100)	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 2,133,170,633	\$ 1,621,208,423	\$ 1,361,631,660	\$ 516,880,446	\$ 589,600,289	\$ 194,908,069	\$ 26,395,514	\$ 79,765,604	\$ 6,523,560,637
Concessional Safety Net	\$ 460,864,021	\$ 332,786,798	\$ 270,418,259	\$ 112,694,316	\$ 110,549,032	\$ 39,561,039	\$ 1,892,947	\$ 13,811,892	\$ 1,342,578,304
General Non-Safety Net	\$ 1,202,106,779	\$ 904,750,337	\$ 662,104,283	\$ 231,920,542	\$ 401,467,758	\$ 74,969,297	\$ 34,107,310	\$ 88,240,262	\$ 3,599,666,568
General Safety Net	\$ 39,830,666	\$ 29,834,713	\$ 22,135,249	\$ 8,547,354	\$ 14,479,949	\$ 2,125,933	\$ 289,059	\$ 3,246,877	\$ 120,489,800
Total	\$ 3,835,972,099	\$ 2,888,580,271	\$ 2,316,289,450	\$ 870,042,658	\$ 1,116,097,027	\$ 311,564,338	\$ 62,684,830	\$ 185,064,636	\$ 11,586,295,309
Total Cost (S85 + S100)*	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Concessional Non-Safety Net	\$ 2,432,848,456	\$ 1,858,789,351	\$ 1,546,721,067	\$ 595,293,556	\$ 670,739,592	\$ 221,415,482	\$ 29,107,831	\$ 89,414,600	\$ 7,444,329,935
Concessional Safety Net	\$ 460,864,021	\$ 332,786,798	\$ 270,418,259	\$ 112,694,316	\$ 110,549,032	\$ 39,561,039	\$ 1,892,947	\$ 13,811,892	\$ 1,342,578,304
General Non-Safety Net	\$ 1,370,294,826	\$ 1,033,379,778	\$ 763,884,033	\$ 266,793,701	\$ 459,303,431	\$ 85,774,877	\$ 37,929,649	\$ 100,797,042	\$ 4,118,157,337
General Safety Net	\$ 45,539,461	\$ 33,810,740	\$ 25,003,509	\$ 9,714,823	\$ 16,230,553	\$ 2,421,026	\$ 333,071	\$ 3,680,191	\$ 136,733,374
Total	\$ 4,309,546,764	\$ 3,258,766,668	\$ 2,606,026,869	\$ 984,496,395	\$ 1,256,822,608	\$ 349,172,423	\$ 69,263,499	\$ 207,703,725	\$ 13,041,798,951
Population Percentage	NSW	VIC	QLD	SA	WA	TAS	NT	ACT	Australia
Population**	7,920,508	6,384,381	4,964,336	1,728,077	2,584,111	524,826	246,871	416,244	24,773,958
PBS S85 Subsidised Scripts per Capita	8.44	7.88	8.18	9.69	6.92	10.82	2.92	5.34	8.11
PBS (S85 + S100) Subsidised Scripts per Capita	8.55	7.98	8.28	9.80	7.02	10.92	3.01	5.54	8.22
PBS S85 Govt Cost per Capita	\$ 351.17	\$ 335.00	\$ 341.20	\$ 378.77	\$ 307.07	\$ 450.56	\$ 136.39	\$ 276.06	\$ 340.97
PBS (S85 + S100) Govt Cost per Capita	\$ 484.31	\$ 452.44	\$ 466.59	\$ 503.47	\$ 431.91	\$ 593.65	\$ 253.92	\$ 444.61	\$ 467.68
Population Percentage	31.97%	25.77%	20.04%	6.98%	10.43%	2.12%	1.00%	1.68%	100.00%
PBS (S85 + S100) Subsidised Scripts Percentage	33.25%	25.03%	20.19%	8.31%	8.91%	2.82%	0.37%	1.13%	100.00%
PBS (S85 + S100) Govt Cost Percentage	33.11%	24.93%	19.99%	7.51%	9.63%	2.69%	0.54%	1.60%	100.00%
Total Cost Percentage	33.04%	24.99%	19.98%	7.55%	9.64%	2.68%	0.53%	1.59%	100.00%

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions (S85 + S100 prescriptions).

**Population 31 December 2017, Source: ABS Publication 3101.0

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 5(a): Top 50 PBS Drugs (Generic Name) Sorted by Highest Government Cost, 2017-18
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	SOFOSBUVIR + VELPATASVIR	31,047	\$ 695,021,028	\$ 598,683	\$ 695,619,711	\$ 22,405.38
2	ADALIMUMAB	228,048	\$ 320,374,082	\$ 6,091,081	\$ 326,465,163	\$ 1,431.56
3	AFLIBERCEPT	239,284	\$ 304,212,258	\$ 3,429,328	\$ 307,641,587	\$ 1,285.68
4	LEDIPASVIR + SOFOSBUVIR	10,976	\$ 244,606,914	\$ 215,671	\$ 244,822,585	\$ 22,305.26
5	NIVOLUMAB	41,839	\$ 208,068,092	\$ 152,119	\$ 208,220,211	\$ 4,976.70
6	SOFOSBUVIR	10,439	\$ 204,285,271	\$ 175,432	\$ 204,460,703	\$ 19,586.23
7	RANIBIZUMAB	160,133	\$ 200,472,514	\$ 2,034,482	\$ 202,506,996	\$ 1,264.62
8	DENOSUMAB	648,197	\$ 182,104,888	\$ 7,487,495	\$ 189,592,383	\$ 292.49
9	TRASTUZUMAB	55,782	\$ 169,401,131	\$ 558,713	\$ 169,959,844	\$ 3,046.86
10	INSULIN GLARGINE	389,177	\$ 145,203,345	\$ 5,549,996	\$ 150,753,341	\$ 387.36
11	FINGOLIMOD	65,743	\$ 143,454,178	\$ 1,732,894	\$ 145,187,072	\$ 2,208.40
12	PEMBROLIZUMAB	16,916	\$ 142,880,020	\$ 73,499	\$ 142,953,519	\$ 8,450.79
13	ELBASVIR + GRAZOPREXIN	6,321	\$ 134,434,092	\$ 107,698	\$ 134,541,790	\$ 21,284.89
14	PREGABALIN	3,754,823	\$ 133,233,517	\$ 38,726,614	\$ 171,960,132	\$ 45.80
15	RIVAROXABAN	1,701,610	\$ 125,750,091	\$ 22,889,774	\$ 148,639,865	\$ 87.35
16	APIXABAN	1,544,809	\$ 125,494,642	\$ 17,454,134	\$ 142,948,776	\$ 92.53
17	RITUXIMAB	42,357	\$ 124,680,015	\$ 336,535	\$ 125,016,550	\$ 2,951.50
18	LENALIDOMIDE	20,148	\$ 123,618,271	\$ 291,758	\$ 123,910,029	\$ 6,149.99
19	INFLIXIMAB	52,250	\$ 120,273,526	\$ 1,632,205	\$ 121,905,731	\$ 2,333.12
20	USTEKINUMAB	18,449	\$ 118,487,252	\$ 542,813	\$ 119,030,066	\$ 6,451.84
21	ESOMEPRAZOLE	6,358,260	\$ 114,340,799	\$ 32,299,196	\$ 146,639,995	\$ 23.06
22	FLUTICASON + SALMETEROL	2,640,693	\$ 105,851,750	\$ 43,799,378	\$ 149,651,128	\$ 56.67
23	ETANERCEPT	98,700	\$ 101,257,225	\$ 2,245,001	\$ 103,502,227	\$ 1,048.65
24	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,939,469	\$ 88,321,175	\$ 35,971,089	\$ 124,292,264	\$ 64.09
25	ENZALUTAMIDE	23,333	\$ 86,726,608	\$ 257,554	\$ 86,984,163	\$ 3,727.95
26	ROSUVASTATIN	6,931,103	\$ 83,479,891	\$ 36,474,397	\$ 119,954,288	\$ 17.31
27	BEVACIZUMAB	37,080	\$ 83,254,756	\$ 142,303	\$ 83,397,059	\$ 2,249.11
28	TIOTROPIUM	1,641,771	\$ 82,198,262	\$ 14,302,018	\$ 96,500,280	\$ 58.78
29	MESALAZINE	322,160	\$ 81,797,837	\$ 8,625,018	\$ 90,422,856	\$ 280.68
30	DACLATASVIR	9,541	\$ 74,597,961	\$ 158,711	\$ 74,756,671	\$ 7,835.31
31	DARBEOETIN ALFA	62,729	\$ 72,649,049	\$ 799,318	\$ 73,448,367	\$ 1,170.88
32	OXYCODONE + NALOXONE	1,800,114	\$ 69,455,071	\$ 12,830,148	\$ 82,285,218	\$ 45.71
33	GOLIMUMAB	52,078	\$ 69,216,293	\$ 1,312,276	\$ 70,528,569	\$ 1,354.29
34	IRON	248,205	\$ 68,160,786	\$ 5,962,430	\$ 74,123,217	\$ 298.64
35	PALIPERIDONE	201,816	\$ 67,549,226	\$ 2,064,130	\$ 69,613,356	\$ 344.93
36	IMATINIB	25,760	\$ 66,205,949	\$ 525,898	\$ 66,731,847	\$ 2,590.52
37	EZETIMIBE	1,298,565	\$ 65,840,737	\$ 18,446,864	\$ 84,287,601	\$ 64.91
38	ATORVASTATIN	7,383,034	\$ 65,173,411	\$ 37,896,217	\$ 103,069,628	\$ 13.96
39	IPILIMUMAB	2,082	\$ 64,374,791	\$ 22,823	\$ 64,397,614	\$ 30,930.65
40	IVACAFTOR	2,760	\$ 62,146,490	\$ 43,557	\$ 62,190,047	\$ 22,532.63
41	BUPRENORPHINE	1,283,291	\$ 60,993,249	\$ 8,757,823	\$ 69,751,072	\$ 54.35
42	GOSERELIN	87,827	\$ 60,960,237	\$ 1,711,429	\$ 62,671,666	\$ 713.58
43	ARIPIPRAZOLE	300,418	\$ 57,381,499	\$ 3,716,132	\$ 61,097,631	\$ 203.38
44	INSULIN ASPART	274,219	\$ 57,233,031	\$ 5,083,255	\$ 62,316,286	\$ 227.25
45	SECUKINUMAB	35,877	\$ 56,898,052	\$ 983,686	\$ 57,881,738	\$ 1,613.34
46	OXYCODONE	2,305,024	\$ 56,826,927	\$ 13,000,424	\$ 69,827,351	\$ 30.29
47	DOLUTEGRAVIR + ABACAVIR + LAMIVUDINE	30,227	\$ 55,151,218	\$ 881,591	\$ 56,032,809	\$ 1,853.73
48	SITAGLIPTIN + METFORMIN	1,283,114	\$ 54,591,267	\$ 21,219,796	\$ 75,811,063	\$ 59.08
49	BORTEZOMIB	36,587	\$ 54,484,175	\$ 45,526	\$ 54,529,701	\$ 1,490.41
50	TRAMETINIB	6,081	\$ 53,693,310	\$ 122,920	\$ 53,816,230	\$ 8,849.90

* Total Cost includes cost to the patient and cost to the government for PBS (S85 + S100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 5(b): Top 50 PBS Drugs (Generic Name) Sorted by Highest Subsidised Prescriptions, 2017-18

Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**
1	ATORVASTATIN	7,383,034	\$ 65,173,411	\$ 37,896,217	\$ 103,069,628	\$ 13.96
2	ROSUVASTATIN	6,931,103	\$ 83,479,891	\$ 36,474,397	\$ 119,954,288	\$ 17.31
3	ESOMEPRAZOLE	6,358,260	\$ 114,340,799	\$ 32,299,196	\$ 146,639,995	\$ 23.06
4	PANTOPRAZOLE	4,841,034	\$ 44,839,394	\$ 24,050,087	\$ 68,889,481	\$ 14.23
5	PERINDOPRIL	3,937,475	\$ 35,724,346	\$ 20,685,362	\$ 56,409,708	\$ 14.33
6	PREGABALIN	3,754,823	\$ 133,233,517	\$ 38,726,614	\$ 171,960,132	\$ 45.80
7	METFORMIN	3,275,874	\$ 33,648,999	\$ 15,501,013	\$ 49,150,012	\$ 15.00
8	SALBUTAMOL	2,929,667	\$ 42,283,059	\$ 12,611,657	\$ 54,894,716	\$ 18.74
9	IRBESARTAN	2,700,323	\$ 22,772,043	\$ 14,096,067	\$ 36,868,110	\$ 13.65
10	FLUTICASONE + SALMETEROL	2,640,693	\$ 105,851,750	\$ 43,799,378	\$ 149,651,128	\$ 56.67
11	CEFALEXIN	2,632,910	\$ 21,378,597	\$ 13,946,311	\$ 35,324,908	\$ 13.42
12	AMLODIPINE	2,378,152	\$ 16,977,308	\$ 12,119,632	\$ 29,096,940	\$ 12.24
13	ATENOLOL	2,318,874	\$ 17,778,141	\$ 11,726,430	\$ 29,504,572	\$ 12.72
14	OXYCODONE	2,305,024	\$ 56,826,927	\$ 13,000,424	\$ 69,827,351	\$ 30.29
15	PARACETAMOL + CODEINE	2,246,812	\$ 27,132,282	\$ 11,327,136	\$ 38,459,418	\$ 17.12
16	RAMIPRIL	2,122,309	\$ 17,743,608	\$ 10,831,884	\$ 28,575,493	\$ 13.46
17	TELMISARTAN	2,087,083	\$ 20,147,353	\$ 11,232,265	\$ 31,379,619	\$ 15.04
18	SIMVASTATIN	2,076,636	\$ 16,759,708	\$ 10,550,755	\$ 27,310,463	\$ 13.15
19	AMOXICILLIN	2,073,067	\$ 16,871,512	\$ 11,418,321	\$ 28,289,833	\$ 13.65
20	AMOXICILLIN + CLAVULANIC ACID	2,043,531	\$ 18,286,603	\$ 10,748,628	\$ 29,035,230	\$ 14.21
21	CANDESARTAN	2,029,152	\$ 17,710,686	\$ 10,734,562	\$ 28,445,248	\$ 14.02
22	SERTRALINE	1,958,407	\$ 15,780,427	\$ 10,431,349	\$ 26,211,776	\$ 13.38
23	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,939,469	\$ 88,321,175	\$ 35,971,089	\$ 124,292,264	\$ 64.09
24	TRAMADOL	1,848,905	\$ 23,680,055	\$ 8,626,602	\$ 32,306,657	\$ 17.47
25	ESCITALOPRAM	1,836,972	\$ 15,232,820	\$ 9,960,770	\$ 25,193,590	\$ 13.71
26	OXYCODONE + NALOXONE	1,800,114	\$ 69,455,071	\$ 12,830,148	\$ 82,285,218	\$ 45.71
27	CLOPIDOGREL	1,796,352	\$ 19,049,156	\$ 8,423,279	\$ 27,472,435	\$ 15.29
28	MIRTAZAPINE	1,793,956	\$ 18,965,763	\$ 8,857,702	\$ 27,823,465	\$ 15.51
29	RABEPRAZOLE	1,752,224	\$ 17,515,735	\$ 8,829,416	\$ 26,345,151	\$ 15.04
30	DIAZEPAM	1,703,465	\$ 12,398,805	\$ 8,486,200	\$ 20,885,006	\$ 12.26
31	RIVAROXABAN	1,701,610	\$ 125,750,091	\$ 22,889,774	\$ 148,639,865	\$ 87.35
32	METOPROLOL TARTRATE	1,699,188	\$ 13,975,109	\$ 8,140,623	\$ 22,115,731	\$ 13.02
33	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,686,706	\$ 15,911,699	\$ 8,912,352	\$ 24,824,050	\$ 14.72
34	VENLAFAXINE	1,671,473	\$ 18,580,289	\$ 8,854,191	\$ 27,434,481	\$ 16.41
35	TIOTROPIUM	1,641,771	\$ 82,198,262	\$ 14,302,018	\$ 96,500,280	\$ 58.78
36	LERCANIDIPINE	1,616,344	\$ 14,580,698	\$ 8,053,912	\$ 22,634,610	\$ 14.00
37	APIXABAN	1,544,809	\$ 125,494,642	\$ 17,454,134	\$ 142,948,776	\$ 92.53
38	OMEPRAZOLE	1,509,981	\$ 17,635,419	\$ 7,536,147	\$ 25,171,567	\$ 16.67
39	PARACETAMOL	1,501,408	\$ 20,322,427	\$ 5,997,082	\$ 26,319,509	\$ 17.53
40	AMITRIPTYLINE	1,489,094	\$ 13,944,234	\$ 7,146,047	\$ 21,090,282	\$ 14.16
41	FUROSEMIDE (FRUSEMIDE)	1,453,814	\$ 12,346,815	\$ 6,316,280	\$ 18,663,095	\$ 12.84
42	WARFARIN	1,452,384	\$ 17,222,366	\$ 6,569,166	\$ 23,791,532	\$ 16.38
43	MELOXICAM	1,378,763	\$ 13,266,621	\$ 7,052,298	\$ 20,318,919	\$ 14.74
44	TEMAZEPAM	1,377,637	\$ 10,179,781	\$ 6,537,096	\$ 16,716,876	\$ 12.13
45	GLICLAZIDE	1,363,176	\$ 18,387,493	\$ 6,177,086	\$ 24,564,579	\$ 18.02
46	PERINDOPRIL + AMLODIPINE	1,314,012	\$ 14,169,120	\$ 7,241,426	\$ 21,410,545	\$ 16.29
47	EZETIMIBE	1,298,565	\$ 65,840,737	\$ 18,446,864	\$ 84,287,601	\$ 64.91
48	PREDNISOLONE	1,284,443	\$ 11,963,465	\$ 6,196,919	\$ 18,160,384	\$ 14.14
49	BUPRENORPHINE	1,283,291	\$ 60,993,249	\$ 8,757,823	\$ 69,751,072	\$ 54.35
50	SITAGLIPTIN + METFORMIN	1,283,114	\$ 54,591,267	\$ 21,219,796	\$ 75,811,063	\$ 59.08

* Total Cost includes cost to the patient and cost to the government for PBS (S85 + S100) subsidised prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 6: Top 50 PBS Drugs (Generic Name) Sorted by Highest Total Prescription Volume, 2017-18
 Section 85 and Section 100[^], including Drs Bag and under co-payment prescriptions

Rank	Drug Name	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescription Volume	Total Government Cost
1	ROSUVASTATIN	6,931,103	4,093,749	11,024,852	\$ 119,954,288
2	ATORVASTATIN	7,383,034	3,218,230	10,601,264	\$ 103,069,628
3	ESOMEPRAZOLE	6,358,260	2,814,013	9,172,273	\$ 146,639,995
4	PANTOPRAZOLE	4,841,034	2,051,664	6,892,698	\$ 68,889,481
5	PERINDOPRIL	3,937,475	2,382,261	6,319,736	\$ 56,409,708
6	CEFALEXIN	2,632,910	2,714,855	5,347,765	\$ 35,324,908
7	AMOXICILLIN	2,073,067	3,142,211	5,215,278	\$ 28,289,833
8	METFORMIN	3,275,874	1,645,350	4,921,224	\$ 49,150,012
9	AMOXICILLIN + CLAVULANIC ACID	2,043,531	2,580,141	4,623,672	\$ 29,035,230
10	ESCITALOPRAM	1,836,972	2,269,508	4,106,480	\$ 25,193,590
11	SERTRALINE	1,958,407	2,077,014	4,035,421	\$ 26,211,776
12	IRBESARTAN	2,700,323	1,310,500	4,010,823	\$ 36,868,110
13	PREGABALIN	3,754,823	200,599	3,955,422	\$ 171,960,132
14	PARACETAMOL + CODEINE	2,246,812	1,503,661	3,750,473	\$ 38,459,418
15	SALBUTAMOL	2,929,667	754,594	3,684,261	\$ 54,894,716
16	TELMISARTAN	2,087,083	1,408,209	3,495,292	\$ 31,379,619
17	OXYCODONE	2,305,024	1,137,980	3,443,004	\$ 69,827,351
18	AMLODIPINE	2,378,152	1,034,692	3,412,844	\$ 29,096,940
19	RAMIPRIL	2,122,309	1,105,751	3,228,060	\$ 28,575,493
20	ATENOLOL	2,318,874	900,632	3,219,506	\$ 29,504,572
21	CANDESARTAN	2,029,152	1,147,360	3,176,512	\$ 28,445,248
22	VENLAFAXINE	1,671,473	1,299,382	2,970,855	\$ 27,434,481
23	TRAMADOL	1,848,905	797,770	2,646,675	\$ 32,306,657
24	FLUTICASONE + SALMETEROL	2,640,693	508	2,641,201	\$ 149,651,128
25	SIMVASTATIN	2,076,636	560,492	2,637,128	\$ 27,310,463
26	RABEPRAZOLE	1,752,224	874,014	2,626,238	\$ 26,345,151
27	IRBESARTAN + HYDROCHLOROTHIAZIDE	1,686,706	803,069	2,489,775	\$ 24,824,050
28	DIAZEPAM	1,703,465	766,909	2,470,374	\$ 20,885,006
29	MIRTAZAPINE	1,793,956	638,364	2,432,320	\$ 27,823,465
30	MELOXICAM	1,378,763	1,021,380	2,400,143	\$ 20,318,919
31	PERINDOPRIL + AMLODIPINE	1,314,012	1,010,734	2,324,746	\$ 21,410,545
32	PREDNISOLONE	1,284,443	985,863	2,270,306	\$ 18,160,384
33	METOPROLOL TARTRATE	1,699,188	531,917	2,231,105	\$ 22,115,731
34	AMITRIPTYLINE	1,489,094	732,863	2,221,957	\$ 21,090,282
35	CLOPIDOGREL	1,796,352	397,001	2,193,353	\$ 27,472,435
36	DESVENLAFAXINE	1,193,701	993,629	2,187,330	\$ 37,473,089
37	DOXYCYCLINE	1,041,696	1,141,456	2,183,152	\$ 14,007,068
38	LERCANIDIPINE	1,616,344	536,841	2,153,185	\$ 22,634,610
39	OXYCODONE + NALOXONE	1,800,114	344,096	2,144,210	\$ 82,285,218
40	OMEPRAZOLE	1,509,981	624,826	2,134,807	\$ 25,171,567
41	LEVONORGESTREL + ETHINYLESTRADIOL	415,538	1,579,537	1,995,075	\$ 7,293,297
42	BUDESONIDE + FORMOTEROL (EFORMOTEROL)	1,939,469	5,120	1,944,589	\$ 124,292,264
43	FLUOXETINE	940,442	994,814	1,935,256	\$ 16,865,999
44	TEMAZEPAM	1,377,637	545,174	1,922,811	\$ 16,716,876
45	WARFARIN	1,452,384	394,497	1,846,881	\$ 23,791,532
46	GLICLAZIDE	1,363,176	472,120	1,835,296	\$ 24,564,579
47	LEVOTHYROXINE	981,000	785,593	1,766,593	\$ 25,555,743
48	CITALOPRAM	961,255	759,084	1,720,339	\$ 12,517,772
49	RIVAROXABAN	1,701,610	1,283	1,702,893	\$ 148,639,865
50	CELECOXIB	977,205	682,709	1,659,914	\$ 17,234,641

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 7: Top 50 ATC Level 2 Drug Groups Sorted by Highest Total Prescription Volume, 2017-18

Section 85 and Section 100[^], including Drs Bag and under co-payment prescriptions

Rank	ATC Level 2 Code	ATC Level 2 Group	PBS Subsidised Prescriptions	Under Co-Payment Prescriptions	Total Prescriptions
1	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	22,871,454	13,458,969	36,330,423
2	C10	LIPID MODIFYING AGENTS	22,074,153	8,427,609	30,501,762
3	N06	PSYCHOANALEPTICS	16,030,633	11,683,969	27,714,602
4	J01	ANTIBACTERIALS FOR SYSTEMIC USE	11,903,275	13,904,792	25,808,067
5	A02	DRUGS FOR ACID RELATED DISORDERS	15,881,654	6,902,226	22,783,880
6	N02	ANALGESICS	17,242,155	5,215,714	22,457,869
7	R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	11,875,343	1,325,383	13,200,726
8	A10	DRUGS USED IN DIABETES	10,923,827	2,224,581	13,148,408
9	N05	PSYCHOLEPTICS	7,779,679	1,930,936	9,710,615
10	B01	ANTITHROMBOTIC AGENTS	8,524,690	999,645	9,524,335
11	C08	CALCIUM CHANNEL BLOCKERS	6,222,546	2,285,740	8,508,286
12	C07	BETA BLOCKING AGENTS	6,230,069	2,129,758	8,359,827
13	S01	OPHTHALMOLOGICALS	6,656,107	1,442,100	8,098,207
14	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	3,686,590	3,099,974	6,786,564
15	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	2,218,984	3,275,336	5,494,320
16	H02	CORTICOSTEROIDS FOR SYSTEMIC USE	2,273,656	1,892,786	4,166,442
17	D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	2,237,324	1,549,605	3,786,929
18	C01	CARDIAC THERAPY	2,880,609	515,037	3,395,646
19	C03	DIURETICS	2,335,329	502,358	2,837,687
20	N03	ANTIEPILEPTICS	2,159,219	663,233	2,822,452
21	M05	DRUGS FOR TREATMENT OF BONE DISEASES	1,890,332	203,683	2,094,015
22	C02	ANTIHYPERTENSIVES	1,581,498	488,236	2,069,734
23	M04	ANTIGOUT PREPARATIONS	1,185,124	744,733	1,929,857
24	H03	THYROID THERAPY	1,096,036	813,274	1,909,310
25	L01	ANTINEOPLASTIC AGENTS	1,625,873	83,057	1,708,930
26	G04	UROLOGICALS	1,384,030	289,632	1,673,662
27	L04	IMMUNOSUPPRESSANTS	1,416,918	137,397	1,554,315
28	A06	DRUGS FOR CONSTIPATION	1,405,520	72,929	1,478,449
29	A04	ANTIEMETICS AND ANTINAUSEANTS	951,411	488,507	1,439,918
30	N04	ANTI-PARKINSON DRUGS	1,182,098	140,887	1,322,985
31	A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	877,314	439,079	1,316,393
32	J05	ANTIVIRALS FOR SYSTEMIC USE	777,963	430,951	1,208,914
33	S02	OTOLOGICALS	579,725	508,131	1,087,856
34	B03	ANTIEMETIC PREPARATIONS	870,909	112,692	983,601
35	L02	ENDOCRINE THERAPY	700,118	279,023	979,141
36	A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	860,363	61,150	921,513
37	N07	OTHER NERVOUS SYSTEM DRUGS	687,097	2,459	689,556
38	D10	ANTI-ACNE PREPARATIONS	220,238	147,361	367,599
39	A12	MINERAL SUPPLEMENTS	301,295	53,900	355,195
40	M03	MUSCLE RELAXANTS	253,211	53,462	306,673
41	D05	ANTIPSORIATICS	224,035	76,578	300,613
42	R05	COUGH AND COLD PREPARATIONS	150,819	72,031	222,850
43	G02	OTHER GYNECOLOGICALS	184,471	6,017	190,488
44	H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	155,539	26	155,565
45	A09	DIGESTIVES, INCL. ENZYMES	154,236	554	154,790
46	A11	VITAMINS	121,457	30,522	151,979
47	A01	STOMATOLOGICAL PREPARATIONS	99,440	46,379	145,819
48	J02	ANTIMYCOTICS FOR SYSTEMIC USE	94,990	43,850	138,840
49	D01	ANTIFUNGALS FOR DERMATOLOGICAL USE	76,108	55,197	131,305
50	V03	ALL OTHER THERAPEUTIC PRODUCTS	109,980	9,385	119,365

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 8: ATC Main Groups Comparison for PBS Subsidised Prescriptions, Government Cost, Patient Contribution and Average Price, 2016-17 and 2017-18

Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

ATC Group Level 1	PBS Subsidised Prescriptions				Government Cost				Patient Contribution***			
	2016-17	2017-18	Prescriptions Change	Percentage Change	2016-17	2017-18	Gov Cost Change	Percentage Change	2016-17	2017-18	Patient Contribution Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	30,959,220	31,618,360	659,140	2.1%	\$ 972,556,071	\$ 1,001,588,908	\$ 29,032,837	3.0%	\$ 220,423,794	\$ 236,103,320	\$ 15,679,526	7.1%
BLOOD AND BLOOD FORMING ORGANS	8,958,311	9,481,968	523,657	5.8%	\$ 574,580,171	\$ 646,335,012	\$ 71,754,841	12.5%	\$ 79,035,028	\$ 90,297,157	\$ 11,262,129	14.2%
CARDIOVASCULAR SYSTEM	63,707,501	64,197,518	490,017	0.8%	\$ 956,459,599	\$ 971,014,518	\$ 14,554,918	1.5%	\$ 368,704,734	\$ 381,027,038	\$ 12,322,305	3.3%
DERMATOLOGICALS	2,839,218	2,848,227	9,009	0.3%	\$ 63,634,146	\$ 65,593,140	\$ 1,958,994	3.1%	\$ 26,071,822	\$ 25,375,722	-\$ 696,100	-2.7%
GENITO URINARY SYSTEM AND SEX HORMONES	3,617,544	3,787,485	169,941	4.7%	\$ 230,115,041	\$ 235,870,949	\$ 5,755,908	2.5%	\$ 33,972,821	\$ 35,655,998	\$ 1,683,177	5.0%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	3,585,368	3,601,992	16,624	0.5%	\$ 156,246,861	\$ 165,717,158	\$ 9,470,297	6.1%	\$ 22,286,655	\$ 23,400,971	\$ 1,114,316	5.0%
ANTIINFECTIVES FOR SYSTEMIC USE	13,656,328	12,829,125	- 827,203	-6.1%	\$ 2,911,351,426	\$ 1,900,454,388	-\$ 1,010,897,038	-34.7%	\$ 86,515,902	\$ 81,295,555	-\$ 5,220,346	-6.0%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	3,675,456	3,853,043	177,587	4.8%	\$ 3,287,989,446	\$ 3,709,317,369	\$ 421,327,922	12.8%	\$ 52,346,008	\$ 55,417,777	\$ 3,071,768	5.9%
MUSCULO-SKELETAL SYSTEM	7,302,930	7,015,306	- 287,624	-3.9%	\$ 312,563,183	\$ 342,156,058	\$ 29,592,875	9.5%	\$ 43,848,686	\$ 42,995,827	-\$ 852,860	-1.9%
NERVOUS SYSTEM	44,486,245	45,097,240	610,995	1.4%	\$ 1,296,181,453	\$ 1,297,478,491	\$ 1,297,039	0.1%	\$ 293,064,617	\$ 300,439,624	\$ 7,375,007	2.5%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	87,064	79,545	- 7,519	-8.6%	\$ 2,333,031	\$ 2,409,510	\$ 76,479	3.3%	\$ 674,824	\$ 655,335	-\$ 19,489	-2.9%
RESPIRATORY SYSTEM	11,961,650	12,046,494	84,844	0.7%	\$ 545,514,298	\$ 552,329,439	\$ 6,815,142	1.2%	\$ 132,127,348	\$ 136,962,559	\$ 4,835,211	3.7%
SENSORY ORGANS	7,188,214	7,266,559	78,345	1.1%	\$ 567,014,932	\$ 627,508,282	\$ 60,493,349	10.7%	\$ 41,507,648	\$ 41,524,534	\$ 16,886	0.0%
VARIOUS	197,360	196,114	- 1,246	-0.6%	\$ 78,705,799	\$ 80,527,983	\$ 1,822,184	2.3%	\$ 3,342,177	\$ 3,399,272	\$ 57,096	1.7%
UNLESS OTHERWISE CLASSIFIED	145,747	140,671	- 5,076	-3.5%	\$ 4,516,870	\$ 4,562,721	\$ 45,850	1.0%	\$ 949,555	\$ 952,953	\$ 3,398	0.4%
TOTAL	202,368,156	204,059,647	1,691,491	0.8%	\$ 11,959,762,329	\$ 11,602,863,926	-\$ 356,898,402	-3.0%	\$ 1,404,871,618	\$ 1,455,503,642	\$ 50,632,023	3.6%

ATC Group Level 1	Total Cost*				Average Price**			
	2016-17	2017-18	Total Cost Change	Percentage Change	2016-17	2017-18	Ave Price Change	Percentage Change
ALIMENTARY TRACT AND METABOLISM	\$ 1,192,979,865	\$ 1,237,692,228	\$ 44,712,364	3.7%	\$ 38.53	\$ 39.14	\$ 0.61	1.6%
BLOOD AND BLOOD FORMING ORGANS	\$ 653,615,199	\$ 736,632,169	\$ 83,016,970	12.7%	\$ 72.96	\$ 77.69	\$ 4.73	6.5%
CARDIOVASCULAR SYSTEM	\$ 1,325,164,333	\$ 1,352,041,556	\$ 26,877,223	2.0%	\$ 20.80	\$ 21.06	\$ 0.26	1.3%
DERMATOLOGICALS	\$ 89,705,968	\$ 90,968,862	\$ 1,262,894	1.4%	\$ 31.60	\$ 31.94	\$ 0.34	1.1%
GENITO URINARY SYSTEM AND SEX HORMONES	\$ 264,087,862	\$ 271,526,947	\$ 7,439,085	2.8%	\$ 73.00	\$ 71.69	-\$ 1.31	-1.8%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	\$ 178,533,516	\$ 189,118,129	\$ 10,584,613	5.9%	\$ 49.80	\$ 52.50	\$ 2.70	5.4%
ANTIINFECTIVES FOR SYSTEMIC USE	\$ 2,997,867,328	\$ 1,981,749,943	-\$ 1,016,117,385	-33.9%	\$ 219.52	\$ 154.47	-\$ 65.05	-29.6%
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	\$ 3,340,335,455	\$ 3,764,735,146	\$ 424,399,691	12.7%	\$ 908.82	\$ 977.08	\$ 68.26	7.5%
MUSCULO-SKELETAL SYSTEM	\$ 356,411,869	\$ 385,151,884	\$ 28,740,015	8.1%	\$ 48.80	\$ 54.90	\$ 6.10	12.5%
NERVOUS SYSTEM	\$ 1,589,246,070	\$ 1,597,918,115	\$ 8,672,045	0.5%	\$ 35.72	\$ 35.43	-\$ 0.29	-0.8%
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	\$ 3,007,855	\$ 3,064,845	\$ 56,990	1.9%	\$ 34.55	\$ 38.53	\$ 3.98	11.5%
RESPIRATORY SYSTEM	\$ 677,641,645	\$ 689,291,998	\$ 11,650,353	1.7%	\$ 56.65	\$ 57.22	\$ 0.57	1.0%
SENSORY ORGANS	\$ 608,522,580	\$ 669,032,816	\$ 60,510,235	9.9%	\$ 84.66	\$ 92.07	\$ 7.41	8.8%
VARIOUS	\$ 82,047,975	\$ 83,927,255	\$ 1,879,279	2.3%	\$ 415.73	\$ 427.95	\$ 12.22	2.9%
UNLESS OTHERWISE CLASSIFIED	\$ 5,466,426	\$ 5,515,673	\$ 49,248	0.9%	\$ 37.51	\$ 39.21	\$ 1.70	4.5%
TOTAL	\$ 13,364,633,947	\$ 13,058,367,568	-\$ 306,266,379	-2.3%	\$ 66.04	\$ 63.99	-\$ 2.05	-3.1%

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 9(a): Top 35 Drugs Sorted by Highest Change to Government Cost, 2016-17 and 2017-18
 Section 85 and Section 100[^], including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2016-17					2017-18					Government Cost Change	Government Cost Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	NIVOLUMAB	1,742	\$ 8,851,369	\$ 6,509	\$ 8,857,878	\$ 5,085	41,839	\$ 208,068,092	\$ 152,119	\$ 208,220,211	\$ 4,977	\$ 199,216,723	2,250.69%
2	ELBASVIR + GRAZOPRE VIR	3,367	\$ 71,557,317	\$ 60,919	\$ 71,618,236	\$ 21,271	6,321	\$ 134,434,092	\$ 107,698	\$ 134,541,790	\$ 21,285	\$ 62,876,775	87.87%
3	AFLIBERCEPT	192,426	\$ 247,344,211	\$ 2,614,284	\$ 249,958,494	\$ 1,299	239,284	\$ 304,212,258	\$ 3,429,328	\$ 307,641,587	\$ 1,286	\$ 56,868,048	22.99%
4	USTEKINUMAB	12,978	\$ 73,421,499	\$ 370,543	\$ 73,792,042	\$ 5,686	18,449	\$ 118,487,252	\$ 542,813	\$ 119,030,066	\$ 6,452	\$ 45,065,754	61.38%
5	TENOFOVIR ALAFENAMIDE + EMTRICITABINE + ELVITEGRAVIR + COBICISTAT	4,030	\$ 7,747,349	\$ 122,708	\$ 7,870,057	\$ 1,953	26,183	\$ 50,260,317	\$ 795,485	\$ 51,055,802	\$ 1,950	\$ 42,512,968	548.74%
6	DENOSUMAB	524,636	\$ 149,157,498	\$ 5,886,699	\$ 155,044,197	\$ 296	648,197	\$ 182,104,888	\$ 7,487,495	\$ 189,592,383	\$ 292	\$ 32,947,390	22.09%
7	APIXABAN	1,110,653	\$ 93,370,928	\$ 12,204,252	\$ 105,575,181	\$ 95	1,544,809	\$ 125,494,642	\$ 17,454,134	\$ 142,948,776	\$ 93	\$ 32,123,714	34.40%
8	LENALIDOMIDE	15,432	\$ 95,469,112	\$ 220,857	\$ 95,689,969	\$ 6,201	20,148	\$ 123,618,271	\$ 291,758	\$ 123,910,029	\$ 6,150	\$ 28,149,159	29.49%
9	EMTRICITABINE + TENOFOVIR ALAFENAMIDE	3,085	\$ 4,319,028	\$ 81,171	\$ 4,400,199	\$ 1,426	22,714	\$ 32,040,685	\$ 592,698	\$ 32,633,382	\$ 1,437	\$ 27,721,657	641.85%
10	FLUTICASONE FUROATE + VILANTEROL	37,372	\$ 1,778,563	\$ 631,869	\$ 2,410,433	\$ 65	529,035	\$ 25,661,804	\$ 8,742,241	\$ 34,404,044	\$ 65	\$ 23,883,241	1,342.84%
11	SACUBITRIL + VALSARTAN	1,961	\$ 369,519	\$ 25,277	\$ 394,796	\$ 201	114,882	\$ 21,565,954	\$ 1,496,067	\$ 23,062,021	\$ 201	\$ 21,196,435	5,736.23%
12	SECUKINUMAB	20,376	\$ 36,482,539	\$ 573,435	\$ 37,055,973	\$ 1,819	35,877	\$ 56,898,052	\$ 983,686	\$ 57,881,738	\$ 1,613	\$ 20,415,513	55.96%
13	IPILIMUMAB	1,465	\$ 46,343,252	\$ 14,942	\$ 46,358,194	\$ 31,644	2,082	\$ 64,374,791	\$ 22,823	\$ 64,397,614	\$ 30,931	\$ 18,031,539	38.91%
14	IRON	184,867	\$ 50,574,022	\$ 4,215,498	\$ 54,789,520	\$ 296	248,205	\$ 68,160,786	\$ 5,962,430	\$ 74,123,217	\$ 299	\$ 17,586,765	34.77%
15	EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE	704	\$ 1,370,514	\$ 21,485	\$ 1,391,999	\$ 1,977	9,359	\$ 17,651,915	\$ 287,593	\$ 17,939,508	\$ 1,917	\$ 16,281,401	1,187.98%
16	RIVAROXABAN	1,490,302	\$ 109,983,952	\$ 19,427,144	\$ 129,411,097	\$ 87	1,701,610	\$ 125,750,091	\$ 22,889,774	\$ 148,639,865	\$ 87	\$ 15,766,138	14.33%
17	ENZALUTAMIDE	19,091	\$ 70,989,632	\$ 197,550	\$ 71,187,182	\$ 3,729	23,333	\$ 86,726,608	\$ 257,554	\$ 86,984,163	\$ 3,728	\$ 15,736,977	22.17%
18	NINTEDANIB	152	\$ 460,523	\$ 2,013	\$ 462,537	\$ 3,043	5,125	\$ 15,184,558	\$ 66,472	\$ 15,251,030	\$ 2,976	\$ 14,724,035	3,197.24%
19	PEMBROLIZUMAB	15,426	\$ 130,607,616	\$ 70,115	\$ 130,677,731	\$ 8,471	16,916	\$ 142,880,020	\$ 73,499	\$ 142,953,519	\$ 8,451	\$ 12,272,404	9.40%
20	IXEKIZUMAB	663	\$ 2,225,175	\$ 20,663	\$ 2,245,837	\$ 3,387	4,215	\$ 14,224,748	\$ 129,374	\$ 14,354,122	\$ 3,405	\$ 11,999,573	539.26%
21	EMPAGLIFLOZIN	239,100	\$ 10,674,075	\$ 3,921,775	\$ 14,595,850	\$ 61	487,988	\$ 22,107,006	\$ 7,948,957	\$ 30,055,963	\$ 62	\$ 11,432,931	107.11%
22	EXENATIDE	319,374	\$ 26,083,601	\$ 4,885,813	\$ 30,969,414	\$ 97	397,490	\$ 36,832,322	\$ 6,049,412	\$ 42,881,734	\$ 108	\$ 10,748,722	41.21%
23	EMPAGLIFLOZIN + METFORMIN	118,137	\$ 5,311,416	\$ 2,236,580	\$ 7,547,996	\$ 64	349,023	\$ 15,912,165	\$ 6,559,986	\$ 22,472,151	\$ 64	\$ 10,600,749	199.58%
24	RUXOLITINIB	8,119	\$ 39,541,505	\$ 109,505	\$ 39,651,009	\$ 4,884	10,242	\$ 49,968,114	\$ 147,390	\$ 50,115,504	\$ 4,893	\$ 10,426,609	26.37%
25	VEDOLIZUMAB	8,826	\$ 27,355,766	\$ 268,681	\$ 27,624,447	\$ 3,130	12,180	\$ 37,744,882	\$ 380,269	\$ 38,125,151	\$ 3,130	\$ 10,389,116	37.98%
26	LEVODOPA + CARBIDOPA	268,961	\$ 41,261,365	\$ 1,770,884	\$ 43,032,249	\$ 160	275,558	\$ 51,014,191	\$ 1,887,234	\$ 52,901,425	\$ 192	\$ 9,752,826	23.64%
27	MEPOLIZUMAB	983	\$ 1,614,932	\$ 25,503	\$ 1,640,435	\$ 1,669	6,815	\$ 11,233,577	\$ 160,711	\$ 11,394,288	\$ 1,672	\$ 9,618,645	595.61%
28	PERTUZUMAB	10,532	\$ 35,084,903	\$ 78,003	\$ 35,162,906	\$ 3,339	13,187	\$ 43,680,704	\$ 95,781	\$ 43,776,486	\$ 3,320	\$ 8,595,801	24.50%
29	TRASTUZUMAB	52,969	\$ 161,043,523	\$ 486,065	\$ 161,529,588	\$ 3,050	55,782	\$ 169,401,131	\$ 558,713	\$ 169,959,844	\$ 3,047	\$ 8,357,608	5.19%
30	PALIPERIDONE	189,336	\$ 59,509,763	\$ 1,884,818	\$ 61,394,581	\$ 324	201,816	\$ 67,549,226	\$ 2,064,130	\$ 69,613,356	\$ 345	\$ 8,039,463	13.51%
31	BRENTUXIMAB VEDOTIN	246	\$ 3,889,464	\$ 1,479	\$ 3,890,942	\$ 15,817	712	\$ 11,714,917	\$ 3,539	\$ 11,718,456	\$ 16,459	\$ 7,825,453	201.20%
32	BOTULINUM TOXIN TYPE A	59,752	\$ 38,886,088	\$ 1,525,269	\$ 40,411,357	\$ 676	69,892	\$ 46,438,943	\$ 1,843,425	\$ 48,282,367	\$ 691	\$ 7,552,854	19.42%
33	ROSUVASTATIN (&) EZETIMIBE	382,583	\$ 19,855,910	\$ 7,249,262	\$ 27,105,172	\$ 71	558,964	\$ 27,379,190	\$ 10,872,778	\$ 38,251,968	\$ 68	\$ 7,523,280	37.89%
34	OLAPARIB	378	\$ 2,632,397	\$ 10,234	\$ 2,642,630	\$ 6,991	1,434	\$ 10,118,184	\$ 35,454	\$ 10,153,638	\$ 7,081	\$ 7,485,787	284.37%
35	OMALIZUMAB	9,786	\$ 10,527,138	\$ 196,607	\$ 10,723,745	\$ 1,096	17,604	\$ 17,740,743	\$ 409,354	\$ 18,150,098	\$ 1,031	\$ 7,213,606	68.52%

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 9(b): Top 35 Drugs Sorted by Highest Change to Subsidised Script Volume, 2016-17 and 2017-18
 Section 85 and Section 100^, including Drs Bag, excluding under co-payment prescriptions

Rank	Drug Name	2016-17					2017-18					Prescription Volume Change	Prescription Volume Change Percentage
		PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**	PBS Subsidised Prescriptions	Government Cost	Patient Contribution***	Total Cost*	Ave. Price**		
1	FLUTICASONE FUROATE + VILANTEROL	37,372	\$ 1,778,563	\$ 631,869	\$ 2,410,433	\$ 64.50	529,035	\$ 25,661,804	\$ 8,742,241	\$ 34,404,044	\$ 65.03	491,663	1,315.59%
2	APIXABAN	1,110,653	\$ 93,370,928	\$ 12,204,252	\$ 105,575,181	\$ 95.06	1,544,809	\$ 125,494,642	\$ 17,454,134	\$ 142,948,776	\$ 92.53	434,156	39.09%
3	ROSUVASTATIN	6,569,605	\$ 97,394,279	\$ 34,069,256	\$ 131,463,535	\$ 20.01	6,931,103	\$ 83,479,891	\$ 36,474,397	\$ 119,954,288	\$ 17.31	361,498	5.50%
4	EMPAGLIFLOZIN	239,100	\$ 10,674,075	\$ 3,921,775	\$ 14,595,850	\$ 61.04	487,988	\$ 22,107,006	\$ 7,948,957	\$ 30,055,963	\$ 61.59	248,888	104.09%
5	EMPAGLIFLOZIN + METFORMIN	118,137	\$ 5,311,416	\$ 2,236,580	\$ 7,547,996	\$ 63.89	349,023	\$ 15,912,165	\$ 6,559,986	\$ 22,472,151	\$ 64.39	230,886	195.44%
6	RIVAROXABAN	1,490,302	\$ 109,983,952	\$ 19,427,144	\$ 129,411,097	\$ 86.84	1,701,610	\$ 125,750,091	\$ 22,889,774	\$ 148,639,865	\$ 87.35	211,308	14.18%
7	DUTASTERIDE + TAMSULOSIN	727,540	\$ 21,524,220	\$ 3,588,437	\$ 25,112,656	\$ 34.52	906,297	\$ 25,518,280	\$ 4,526,802	\$ 30,045,082	\$ 33.15	178,757	24.57%
8	ROSUVASTATIN (&) EZETIMIBE	382,583	\$ 19,855,910	\$ 7,249,262	\$ 27,105,172	\$ 70.85	558,964	\$ 27,379,190	\$ 10,872,778	\$ 38,251,968	\$ 68.43	176,381	46.10%
9	PREGABALIN	3,580,034	\$ 157,631,393	\$ 37,291,012	\$ 194,922,405	\$ 54.45	3,754,823	\$ 133,233,517	\$ 38,726,614	\$ 171,960,132	\$ 45.80	174,789	4.88%
10	CHLORAMPHENICOL	17,989	\$ 155,777	\$ 103,635	\$ 259,412	\$ 14.42	186,881	\$ 1,806,067	\$ 994,545	\$ 2,800,613	\$ 14.99	168,892	938.86%
11	TAPENTADOL	422,986	\$ 14,299,428	\$ 3,692,166	\$ 17,991,594	\$ 42.53	579,628	\$ 19,845,303	\$ 4,983,509	\$ 24,828,812	\$ 42.84	156,642	37.03%
12	EZETIMIBE	1,149,086	\$ 60,644,119	\$ 15,618,941	\$ 76,263,060	\$ 66.37	1,298,565	\$ 65,840,737	\$ 18,446,864	\$ 84,287,601	\$ 64.91	149,479	13.01%
13	PANTOPRAZOLE	4,707,121	\$ 43,605,160	\$ 23,096,565	\$ 66,701,725	\$ 14.17	4,841,034	\$ 44,839,394	\$ 24,050,087	\$ 68,889,481	\$ 14.23	133,913	2.84%
14	SITAGLIPTIN + METFORMIN	1,155,224	\$ 48,851,266	\$ 18,867,632	\$ 67,718,898	\$ 58.62	1,283,114	\$ 54,591,267	\$ 21,219,796	\$ 75,811,063	\$ 59.08	127,890	11.07%
15	DENOSUMAB	524,636	\$ 149,157,498	\$ 5,886,699	\$ 155,044,197	\$ 295.53	648,197	\$ 182,104,888	\$ 7,487,495	\$ 189,592,383	\$ 292.49	123,561	23.55%
16	SACUBITRIL + VALSARTAN	1,961	\$ 369,519	\$ 25,277	\$ 394,796	\$ 201.32	114,882	\$ 21,565,954	\$ 1,496,067	\$ 23,062,021	\$ 200.75	112,921	5,758.34%
17	ATORVASTATIN	7,273,921	\$ 65,999,005	\$ 36,699,795	\$ 102,698,800	\$ 14.12	7,383,034	\$ 65,173,411	\$ 37,896,217	\$ 103,069,628	\$ 13.96	109,113	1.50%
18	MIRTAZAPINE	1,690,154	\$ 18,086,335	\$ 8,256,242	\$ 26,342,577	\$ 15.59	1,793,956	\$ 18,965,763	\$ 8,857,702	\$ 27,823,465	\$ 15.51	103,802	6.14%
19	BISOPROLOL	953,179	\$ 16,678,006	\$ 4,570,025	\$ 21,248,031	\$ 22.29	1,055,260	\$ 15,860,070	\$ 5,113,440	\$ 20,973,511	\$ 19.88	102,081	10.71%
20	ESCITALOPRAM	1,746,965	\$ 14,424,780	\$ 9,357,758	\$ 23,782,538	\$ 13.61	1,836,972	\$ 15,232,820	\$ 9,960,770	\$ 25,193,590	\$ 13.71	90,007	5.15%
21	OXYCODONE + NALOXONE	1,711,433	\$ 65,638,816	\$ 12,043,561	\$ 77,682,377	\$ 45.39	1,800,114	\$ 69,455,071	\$ 12,830,148	\$ 82,285,218	\$ 45.71	88,681	5.18%
22	DAPAGLIFLOZIN + METFORMIN	161,563	\$ 6,613,116	\$ 3,120,132	\$ 9,733,247	\$ 60.24	243,773	\$ 10,025,300	\$ 4,790,391	\$ 14,815,691	\$ 60.78	82,210	50.88%
23	TIOTROPIUM + OLODATEROL	87,587	\$ 7,041,114	\$ 795,883	\$ 7,836,997	\$ 89.48	168,147	\$ 13,451,924	\$ 1,572,291	\$ 15,024,215	\$ 89.35	80,560	91.98%
24	DABIGATRAN	367,943	\$ 28,386,706	\$ 3,893,558	\$ 32,280,264	\$ 87.73	446,432	\$ 34,428,841	\$ 4,969,421	\$ 39,398,262	\$ 88.25	78,489	21.33%
25	EXENATIDE	319,374	\$ 26,083,601	\$ 4,885,813	\$ 30,969,414	\$ 96.97	397,490	\$ 36,832,322	\$ 6,049,412	\$ 42,881,734	\$ 107.88	78,116	24.46%
26	LINAGLIPTIN	272,398	\$ 13,774,941	\$ 2,811,588	\$ 16,586,529	\$ 60.89	346,320	\$ 17,128,341	\$ 3,486,726	\$ 20,615,068	\$ 59.53	73,922	27.14%
27	PERINDOPRIL + AMLODIPINE	1,244,520	\$ 14,062,812	\$ 6,759,941	\$ 20,822,753	\$ 16.73	1,314,012	\$ 14,169,120	\$ 7,241,426	\$ 21,410,545	\$ 16.29	69,492	5.58%
28	AMLODIPINE	2,311,079	\$ 15,908,757	\$ 11,569,721	\$ 27,478,478	\$ 11.89	2,378,152	\$ 16,977,308	\$ 12,119,632	\$ 29,096,940	\$ 12.24	67,073	2.90%
29	LISDEXAMFETAMINE	146,832	\$ 14,229,308	\$ 2,905,898	\$ 17,135,206	\$ 116.70	210,910	\$ 20,500,087	\$ 4,226,044	\$ 24,726,131	\$ 117.24	64,078	43.64%
30	IRON	184,867	\$ 50,574,022	\$ 4,215,498	\$ 54,789,520	\$ 296.37	248,205	\$ 68,160,786	\$ 5,962,430	\$ 74,123,217	\$ 298.64	63,338	34.26%
31	OLMESARTAN	663,479	\$ 11,329,619	\$ 3,635,418	\$ 14,965,037	\$ 22.56	720,312	\$ 12,070,910	\$ 3,992,972	\$ 16,063,882	\$ 22.30	56,833	8.57%
32	NETUPITANT + PALONOSETRON	11,589	\$ 1,044,391	\$ 305,168	\$ 1,349,559	\$ 116.45	68,186	\$ 5,901,129	\$ 1,659,254	\$ 7,560,383	\$ 110.88	56,597	488.37%
33	SERTRALINE	1,903,115	\$ 14,852,043	\$ 10,013,228	\$ 24,865,271	\$ 13.07	1,958,407	\$ 15,780,427	\$ 10,431,349	\$ 26,211,776	\$ 13.38	55,292	2.91%
34	RANITIDINE	696,104	\$ 6,961,332	\$ 3,260,413	\$ 10,221,746	\$ 14.68	749,416	\$ 7,461,826	\$ 3,550,863	\$ 11,012,689	\$ 14.70	53,312	7.66%
35	PARACETAMOL + CODEINE	2,195,279	\$ 24,172,731	\$ 10,527,810	\$ 34,700,540	\$ 15.81	2,246,812	\$ 27,132,282	\$ 11,327,136	\$ 38,459,418	\$ 17.12	51,533	2.35%

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Average Price is Total Cost divided by PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

^ Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 10(a): PBS Section 85 Prescription Volume, 2014-15 to 2017-18

Section 85 only, including Drs Bag and under co-payment prescriptions

Prescription Type	2014-15	2015-16	2016-17	2017-18
Over Co-payment	204,431,968	204,003,266	199,781,324	201,413,857
Under Co-payment	76,739,457	81,426,548	86,195,858	89,432,000
Total	281,171,425	285,429,814	285,977,182	290,845,857





Table 10(b): PBS Section 85 expenditure, 2014-15 to 2017-18

Section 85 only, including Drs Bag, excluding under co-payment prescriptions

Expenditure Type	2014-15	2015-16	2016-17	2017-18
Government Cost	\$ 6,851,578,963	\$ 8,052,437,581	\$ 8,890,155,516	\$ 8,463,751,877
Patient Contribution***	\$ 1,404,259,396	\$ 1,362,661,089	\$ 1,366,189,392	\$ 1,415,320,507
Total Cost*	\$ 8,255,838,359	\$ 9,415,098,670	\$ 10,256,344,908	\$ 9,879,072,384



* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

*** The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 11: PBS Prescriptions and Government Cost by Formulary, 2017-18

Section 85 and Section 100[^], including under co-payment prescriptions and Drs Bag

Formulary Group ¹	PBS Subsidised Prescriptions	Under co-payment Prescriptions	Total Prescriptions	Percentage	Government Cost	Percentage
F1	29,739,062	3,078,756	32,817,818	11.2%	\$ 6,570,821,952	56.6%
F2	162,624,731	85,123,174	247,747,905	84.4%	\$ 3,329,649,307	28.7%
Combination Drugs ²	11,547,551	1,253,081	12,800,632	4.4%	\$ 1,697,672,811	14.6%
Other ³	148,303	39,699	188,002	0.1%	\$ 4,719,855	0.0%
Total	204,059,647	89,494,710	293,554,357	100.0%	\$ 11,602,863,926	100.0%

Notes:

1. The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2.
Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands.
Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply.
Allocation to F1 or F2 is determined by legislative instrument.
 2. Combination Drugs are not allocated to any formulary.
 3. The category 'Other' includes extemporaneously prepared items.
- [^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 12(a): Top 20 Responsible Persons by Total Cost, 2017-18

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	GILEAD SCIENCES PTY LIMITED	167,255	n.p.	167,255	\$ 1,299,379,007	\$ 4,275,123	\$ 1,303,654,130	\$ 1,276,078,548
2	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,129,736	1,262,751	6,392,487	\$ 917,282,032	\$ 43,387,514	\$ 960,669,546	\$ 827,605,779
3	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	7,890,066	1,497,548	9,387,614	\$ 531,735,683	\$ 99,121,796	\$ 630,857,479	\$ 528,370,217
4	ALPHAPHARM PTY LTD	31,974,672	16,410,925	48,385,597	\$ 461,642,809	\$ 168,359,174	\$ 630,001,983	\$ 314,477,203
5	JANSSEN-CILAG PTY LTD	2,001,274	408,391	2,409,665	\$ 562,694,704	\$ 20,017,603	\$ 582,712,306	\$ 491,415,023
6	PFIZER AUSTRALIA PTY LTD	11,977,374	4,952,040	16,929,414	\$ 478,341,022	\$ 96,980,777	\$ 575,321,799	\$ 438,451,148
7	BAYER AUSTRALIA LTD	3,152,933	1,529,322	4,682,255	\$ 512,016,144	\$ 39,124,471	\$ 551,140,615	\$ 480,889,234
8	APOTEX PTY LTD	30,676,856	13,237,316	43,914,172	\$ 387,152,876	\$ 161,636,684	\$ 548,789,560	\$ 230,569,246
9	ASTRAZENECA PTY LTD	12,725,878	3,476,072	16,201,950	\$ 415,544,868	\$ 116,600,667	\$ 532,145,535	\$ 386,483,962
10	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,834,311	3,521,645	12,355,956	\$ 359,930,885	\$ 55,521,255	\$ 415,452,140	\$ 301,043,855
11	ABBVIE PTY LTD	270,221	44	270,265	\$ 399,592,219	\$ 6,671,696	\$ 406,263,916	\$ 369,803,470
12	AMGEN AUSTRALIA PTY LIMITED	758,124	-	758,124	\$ 319,878,463	\$ 9,513,724	\$ 329,392,187	\$ 269,453,567
13	BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD	1,695,378	375	1,695,753	\$ 305,709,650	\$ 20,453,930	\$ 326,163,580	\$ 286,639,410
14	BOEHRINGER INGELHEIM PTY LTD	6,755,472	1,592,530	8,348,002	\$ 258,508,513	\$ 59,134,579	\$ 317,643,091	\$ 235,569,365
15	SANDOZ PTY LTD	14,105,876	15,831,282	29,937,158	\$ 206,467,142	\$ 79,780,404	\$ 286,247,545	\$ 181,169,357
16	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,640,437	784,959	6,425,396	\$ 217,195,552	\$ 67,388,578	\$ 284,584,130	\$ 200,147,734
17	ROCHE PRODUCTS PTY LTD	955,552	317,942	1,273,494	\$ 229,934,718	\$ 9,211,430	\$ 239,146,148	\$ 185,697,701
18	MUNDIPHARMA PTY LIMITED	4,773,877	649,404	5,423,281	\$ 194,273,180	\$ 36,478,574	\$ 230,751,754	\$ 157,872,577
19	ARROW PHARMA PTY LTD	12,156,539	4,774,393	16,930,932	\$ 147,969,832	\$ 64,418,951	\$ 212,388,783	\$ 91,116,619
20	NOVO NORDISK PHARMACEUTICALS PTY LIMITED	1,032,752	302,851	1,335,603	\$ 152,856,280	\$ 11,887,559	\$ 164,743,839	\$ 148,342,187

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

n.p. - Not Published. Cells with fewer than 6 prescriptions have been suppressed and excluded from totals.

Table 12(b): Top 20 Responsible Persons by PBS Subsidised Prescriptions, 2017-18

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	ALPHAPHARM PTY LTD	31,974,672	16,410,925	48,385,597	\$ 461,642,809	\$ 168,359,174	\$ 630,001,983	\$ 314,477,203
2	APOTEX PTY LTD	30,676,856	13,237,316	43,914,172	\$ 387,152,876	\$ 161,636,684	\$ 548,789,560	\$ 230,569,246
3	SANDOZ PTY LTD	14,105,876	15,831,282	29,937,158	\$ 206,467,142	\$ 79,780,404	\$ 286,247,545	\$ 181,169,357
4	ASTRAZENECA PTY LTD	12,725,878	3,476,072	16,201,950	\$ 415,544,868	\$ 116,600,667	\$ 532,145,535	\$ 386,483,962
5	ARROW PHARMA PTY LTD	12,156,539	4,774,393	16,930,932	\$ 147,969,832	\$ 64,418,951	\$ 212,388,783	\$ 91,116,619
6	PFIZER AUSTRALIA PTY LTD	11,977,374	4,952,040	16,929,414	\$ 478,341,022	\$ 96,980,777	\$ 575,321,799	\$ 438,451,148
7	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,834,311	3,521,645	12,355,956	\$ 359,930,885	\$ 55,521,255	\$ 415,452,140	\$ 301,043,855
8	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	7,890,066	1,497,548	9,387,614	\$ 531,735,683	\$ 99,121,796	\$ 630,857,479	\$ 528,370,217
9	BOEHRINGER INGELHEIM PTY LTD	6,755,472	1,592,530	8,348,002	\$ 258,508,513	\$ 59,134,579	\$ 317,643,091	\$ 235,569,365
10	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,640,437	784,959	6,425,396	\$ 217,195,552	\$ 67,388,578	\$ 284,584,130	\$ 200,147,734
11	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,129,736	1,262,751	6,392,487	\$ 917,282,032	\$ 43,387,514	\$ 960,669,546	\$ 827,605,779
12	MUNDIPHARMA PTY LIMITED	4,773,877	649,404	5,423,281	\$ 194,273,180	\$ 36,478,574	\$ 230,751,754	\$ 157,872,577
13	ASPEN PHARMA PTY LTD	4,484,603	2,377,784	6,862,387	\$ 71,922,061	\$ 25,227,617	\$ 97,149,678	\$ 44,438,197
14	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	4,464,301	4,003,222	8,467,523	\$ 67,172,349	\$ 24,758,366	\$ 91,930,715	\$ 58,235,736
15	MYLAN HEALTH PTY LTD	3,476,387	1,139,672	4,616,059	\$ 84,887,268	\$ 28,996,942	\$ 113,884,211	\$ 80,122,873
16	FAWNS AND MCALLAN PROPRIETARY LIMITED	3,176,741	1,983,543	5,160,284	\$ 43,750,906	\$ 15,646,135	\$ 59,397,041	\$ 34,986,573
17	BAYER AUSTRALIA LTD	3,152,933	1,529,322	4,682,255	\$ 512,016,144	\$ 39,124,471	\$ 551,140,615	\$ 480,889,234
18	SERVIER LABORATORIES (AUST.) PTY LTD	2,636,744	1,517,397	4,154,141	\$ 40,831,679	\$ 14,583,976	\$ 55,415,655	\$ 31,342,686
19	AMNEAL PHARMACEUTICALS PTY LTD	2,097,162	1,115,182	3,212,344	\$ 27,253,881	\$ 11,001,524	\$ 38,255,405	\$ 17,069,626
20	JANSSEN-CILAG PTY LTD	2,001,274	408,391	2,409,665	\$ 562,694,704	\$ 20,017,603	\$ 582,712,306	\$ 491,415,023

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 12(c): Top 20 Responsible Persons by Total PBS Prescriptions, 2017-18

Section 85 and Section 100[^] excluding Efficient Funding of Chemotherapy items, including Drs Bag and under co-payment prescriptions

Rank	Responsible Person	PBS Subsidised Prescriptions	Under Co-payment Prescriptions	Total PBS Prescriptions	Government Cost	Patient Contribution (Subsidised Prescriptions only) ***	Total Cost*	Derived Ex-Manufacturer Sales **
1	ALPHAPHARM PTY LTD	31,974,672	16,410,925	48,385,597	\$ 461,642,809	\$ 168,359,174	\$ 630,001,983	\$ 314,477,203
2	APOTEX PTY LTD	30,676,856	13,237,316	43,914,172	\$ 387,152,876	\$ 161,636,684	\$ 548,789,560	\$ 230,569,246
3	SANDOZ PTY LTD	14,105,876	15,831,282	29,937,158	\$ 206,467,142	\$ 79,780,404	\$ 286,247,545	\$ 181,169,357
4	ARROW PHARMA PTY LTD	12,156,539	4,774,393	16,930,932	\$ 147,969,832	\$ 64,418,951	\$ 212,388,783	\$ 91,116,619
5	PFIZER AUSTRALIA PTY LTD	11,977,374	4,952,040	16,929,414	\$ 478,341,022	\$ 96,980,777	\$ 575,321,799	\$ 438,451,148
6	ASTRAZENECA PTY LTD	12,725,878	3,476,072	16,201,950	\$ 415,544,868	\$ 116,600,667	\$ 532,145,535	\$ 386,483,962
7	SANOFI-AVENTIS AUSTRALIA PTY LTD	8,834,311	3,521,645	12,355,956	\$ 359,930,885	\$ 55,521,255	\$ 415,452,140	\$ 301,043,855
8	MERCK SHARP & DOHME (AUSTRALIA) PTY LTD	7,890,066	1,497,548	9,387,614	\$ 531,735,683	\$ 99,121,796	\$ 630,857,479	\$ 528,370,217
9	ASPEN PHARMACARE AUSTRALIA PTY LIMITED	4,464,301	4,003,222	8,467,523	\$ 67,172,349	\$ 24,758,366	\$ 91,930,715	\$ 58,235,736
10	BOEHRINGER INGELHEIM PTY LTD	6,755,472	1,592,530	8,348,002	\$ 258,508,513	\$ 59,134,579	\$ 317,643,091	\$ 235,569,365
11	ASPEN PHARMA PTY LTD	4,484,603	2,377,784	6,862,387	\$ 71,922,061	\$ 25,227,617	\$ 97,149,678	\$ 44,438,197
12	GLAXOSMITHKLINE AUSTRALIA PTY LTD	5,640,437	784,959	6,425,396	\$ 217,195,552	\$ 67,388,578	\$ 284,584,130	\$ 200,147,734
13	NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED	5,129,736	1,262,751	6,392,487	\$ 917,282,032	\$ 43,387,514	\$ 960,669,546	\$ 827,605,779
14	MUNDIPHARMA PTY LIMITED	4,773,877	649,404	5,423,281	\$ 194,273,180	\$ 36,478,574	\$ 230,751,754	\$ 157,872,577
15	FAWNS AND MCALLAN PROPRIETARY LIMITED	3,176,741	1,983,543	5,160,284	\$ 43,750,906	\$ 15,646,135	\$ 59,397,041	\$ 34,986,573
16	BAYER AUSTRALIA LTD	3,152,933	1,529,322	4,682,255	\$ 512,016,144	\$ 39,124,471	\$ 551,140,615	\$ 480,889,234
17	MYLAN HEALTH PTY LTD	3,476,387	1,139,672	4,616,059	\$ 84,887,268	\$ 28,996,942	\$ 113,884,211	\$ 80,122,873
18	SERVIER LABORATORIES (AUST.) PTY LTD	2,636,744	1,517,397	4,154,141	\$ 40,831,679	\$ 14,583,976	\$ 55,415,655	\$ 31,342,686
19	AMNEAL PHARMACEUTICALS PTY LTD	2,097,162	1,115,182	3,212,344	\$ 27,253,881	\$ 11,001,524	\$ 38,255,405	\$ 17,069,626
20	JANSSEN-CILAG PTY LTD	2,001,274	408,391	2,409,665	\$ 562,694,704	\$ 20,017,603	\$ 582,712,306	\$ 491,415,023

* Total Cost includes cost to the patient and cost to the government for PBS Subsidised Prescriptions.

** Derived Ex-Manufacturer Sales is derived by subtracting the Wholesale Margin amount from the Price to Pharmacist for Dispensed Quantity (per script).

*** The patient contribution includes the cost to the patient for PBS subsidised prescriptions. The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 13: Number of PBS Approved Suppliers, 30 June 2018

Pharmacy State	Number of Community Pharmacies	Number of Private Hospitals	Number of Public Hospitals (Pharmaceutical Reforms)	Number of Dispensing Doctors
NSW	1,878	42	-	3
Vic	1,360	37	69	1
Qld	1,138	35	51	1
SA	454	9	15	1
WA	623	5	20	3
Tas	153	4	4	2
NT	39	1	5	-
ACT	78	4	-	-
Total	5,723	137	164	11

Table 14: PBS Brand Premiums, 2017-18

Section 85 and Section 100[^], excluding Drs Bag and under co-payment prescriptions

	2017-18
Number of brands listed on the PBS(a)	5,292
Number of brands with a premium(a)	358
% of brands with a premium	6.8%
Average brand premium	\$4.46
Weighted average brand premium(b)	\$3.71
Brand premium range	\$0.25 to \$35.30
Prescriptions (millions) dispensed with a brand premium	31.3
Prescriptions (millions) dispensed at the benchmark level (c)	110.6
% of prescriptions dispensed at benchmark level	78.0%

Notes:

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength' as at June 2018 PBS Schedule.

(b) Weighted average brand premium is calculated by:

total premium value / total prescriptions with a premium = weighted average brand premium

(c) Includes only items where at least one brand is listed with a premium.

[^] Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 15(a) PBS/RPBS prescriptions dispensed by Community Pharmacies, 2017-18

Section 85 and Section 100*, excluding Drs Bag and under co-payment prescriptions

Prescription Type	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
Discounted	52,201,149	28%	4,452,294	28%	1,501,647	17%	58,155,090	28%
Non-Discounted	131,908,236	72%	11,725,425	72%	7,290,844	83%	150,924,505	72%
Grand Total	184,109,385	100%	16,177,719	100%	8,792,491	100%	209,079,595	100%

Table 15(b) PBS/RPBS prescriptions by Discount Range dispensed by Community Pharmacies, 2017-18

Section 85 and Section 100^, excluding Drs Bag and under co-payment prescriptions

Discount Range	Concessional		General		RPBS		Total	
	Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
\$1.00	50,542,260	96.8%	4,371,450	98.2%	1,441,310	96.0%	56,355,020	96.9%
0.50 - LT \$1.00	446,153	0.9%	36,411	0.8%	15,820	1.1%	498,384	0.9%
LT 50c	801,805	1.5%	23,109	0.5%	30,630	2.0%	855,544	1.5%
Other	410,931	0.8%	21,324	0.5%	13,887	0.9%	446,142	0.8%
Grand Total	52,201,149	100.0%	4,452,294	100.0%	1,501,647	100.0%	58,155,090	100.0%

^ Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 16(a): PBS/RPBS Continued Dispensing Medicines Prescriptions by Dispensing Pharmacy State, 2017-18

Section 85 and Section 100^, including Drs Bag and under co-payment prescriptions

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	1,204	905	218	182	288	262	4	268	3,331
FLUVASTATIN	1	2	-	1	-	-	-	-	4
LEVONORGESTREL	23	27	20	11	11	21	1	13	127
LEVONORGESTREL + ETHINYLESTRADIOL	861	783	274	246	223	389	13	177	2,966
NORETHISTERONE	5	2	3	2	4	1	-	3	20
NORETHISTERONE + ETHINYLESTRADIOL	91	48	30	16	15	39	1	18	258
NORETHISTERONE + MESTRANOL	5	11	3	-	2	3	-	-	24
PRAVASTATIN	71	46	5	10	5	13	-	15	165
ROSUVASTATIN	1,338	937	223	200	219	313	2	197	3,429
SIMVASTATIN	294	231	33	46	54	85	-	70	813
Grand Total	3,893	2,992	809	714	821	1,126	21	761	11,137

Table 16(b): PBS/RPBS Continued Dispensing Medicines Government Cost by Dispensing Pharmacy State, 2017-18

Section 85 and Section 100^, including Drs Bag and under co-payment prescriptions

Drug Name	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	National
ATORVASTATIN	\$ 7,319	\$ 5,413	\$ 1,186	\$ 1,111	\$ 1,623	\$ 1,458	\$ 13	\$ 1,423	\$ 19,546
FLUVASTATIN	\$ 6	\$ 46	\$ -	\$ 39	\$ -	\$ -	\$ -	\$ -	\$ 91
LEVONORGESTREL	\$ 34	\$ 95	\$ 28	\$ 41	\$ 34	\$ 69	\$ -	\$ 40	\$ 339
LEVONORGESTREL + ETHINYLESTRADIOL	\$ 2,138	\$ 2,062	\$ 603	\$ 448	\$ 327	\$ 1,348	\$ -	\$ 306	\$ 7,232
NORETHISTERONE	\$ 14	\$ -	\$ 14	\$ -	\$ 40	\$ -	\$ -	\$ -	\$ 67
NORETHISTERONE + ETHINYLESTRADIOL	\$ 220	\$ 135	\$ 81	\$ 27	\$ 27	\$ 135	\$ -	\$ 14	\$ 638
NORETHISTERONE + MESTRANOL	\$ -	\$ 40	\$ -	\$ -	\$ 14	\$ 13	\$ -	\$ -	\$ 67
PRAVASTATIN	\$ 519	\$ 357	\$ 24	\$ 84	\$ 47	\$ 157	\$ -	\$ 87	\$ 1,276
ROSUVASTATIN	\$ 9,477	\$ 6,508	\$ 1,354	\$ 1,468	\$ 1,236	\$ 2,541	\$ -	\$ 1,131	\$ 23,715
SIMVASTATIN	\$ 1,800	\$ 1,374	\$ 189	\$ 313	\$ 324	\$ 419	\$ -	\$ 370	\$ 4,789
Grand Total	\$ 21,527	\$ 16,028	\$ 3,479	\$ 3,531	\$ 3,671	\$ 6,140	\$ 13	\$ 3,371	\$ 57,761

^ Excludes Section 100 prescriptions supplied through Remote Area Aboriginal Health Services.

Table 17: Remuneration for Community Pharmacies and Friendly Societies¹, 2017-18
Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenses for PBS and RPBS Prescriptions	2016-17	2017-18	Change	Percentage Change
Price to Pharmacists					
	Ex-Manufacturer Price	\$7,434,882,215	\$7,091,690,186	-\$343,192,029	-4.6%
	Wholesale Mark-up	\$378,887,812	\$387,773,723	\$8,885,911	2.3%
	Sub total	\$7,813,770,027	\$7,479,463,909	-\$334,306,118	-4.3%
Administration, Handling and Storage Costs					
	AHI fee*	\$857,995,456	\$947,411,407	\$89,415,952	10.4%
	Sub total	\$857,995,456	\$947,411,407	\$89,415,952	10.4%
	*Administration, Handling and Infrastructure fee, formerly known as Pharmacy Mark-up				
Pharmacist's Specialised Skills in Dispensing the Medicines					
	Dispensing Fee	\$1,446,886,422	\$1,478,798,859	\$31,912,437	2.2%
	Dangerous Drug Fee	\$24,844,862	\$25,521,423	\$676,561	2.7%
	Wastage	\$3,699,051	\$4,294,442	\$595,391	16.1%
	Container Fee	\$318,292	\$467,183	\$148,891	46.8%
	Sub total	\$1,475,748,626	\$1,509,081,907	\$33,333,280	2.3%
Other					
	Premium Free Dispensing Incentive	\$122,436,617	\$130,505,956	\$8,069,339	6.6%
	Electronic Prescription Fee ²	\$8,855,824	\$11,495,194	\$2,639,370	29.8%
	Sub total	\$131,292,441	\$142,001,150	\$10,708,709	8.2%
Total³	\$10,278,806,550	\$10,077,958,373	-\$200,848,177	-2.0%	

Summary of Medicines, Wholesalers, and Pharmacy Costs

Medicines cost	\$7,434,882,215	\$7,091,690,186	-\$343,192,029	-4.6%
Wholesale cost	\$378,887,812	\$387,773,723	\$8,885,911	2.3%
Pharmacy cost	\$2,465,036,523	\$2,598,494,464	\$133,457,941	5.4%
Total	\$10,278,806,550	\$10,077,958,373	-\$200,848,177	-2.0%

1. Table 17 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

It does not include:

- * Efficient Funding of Chemotherapy (EFC);
- * hospital PBS claims for s85 items (as the report's focus is on community pharmacy);
- * some private hospital HSD claims; and
- * most public hospital HSD claims.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

2. The Electronic Prescription Fee (EPF) is listed as a programme under 6CPA.

3. Health's 2017-18 Annual Report lists the administered expenses for pharmaceutical benefits as \$11.7 billion. The difference between that figure and the total figure above is attributable to:
- * the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and some s100 data for community pharmacy and friendly societies only (it excludes a number of smaller s100 programmes, for example the Opiate Dependence Treatment Program and Remote Area Aboriginal Health Services Programme).
 - * the annual report data is based on accrual figures, whilst the above data is cash basis;
 - * the annual report does not include patient contributions;
 - * the annual report data does not include the Premium Free Dispensing Incentive (PFDI) or EPF;
 - * the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS.

Table 18: CPA Professional Pharmacy Programmes Expenditure, 2017-18

Under the Sixth CPA there were a range of professional programmes and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programmes under CPA in 2017-18 by relevant categories.

Program Type	Actual Expenditure
Rural Pharmacy Maintenance Allowance	\$14,099,312
Rural Pharmacy Workforce Program	\$4,615,944
Medication Management services	\$71,482,115
Medication Adherence services	\$78,554,099
Aboriginal & Torres Strait Islander programs	\$5,618,708
Pharmacy Guild administration fees	\$7,649,772
Programs Total	\$182,019,950

Notes:

1. For the Programs administration arrangements for 2017-18 (administered by the Pharmacy Guild), the total funding provided to the Pharmacy Guild was \$182,019,950 (accrual figure). Of this, \$7,649,772 was provided to the Pharmacy Guild for the purpose of Pharmacy Guild administration fees. This means the Pharmacy Guild administration fees was 4.2% of the total funds.
2. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 17 of the report.
3. Rural Pharmacy Workforce Program, Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

Rural Pharmacy Workforce Program consists of the following elements:	Actual Expenditure
Rural Pharmacist Pre-Reg Inc Allowance Pharmacy - Intern Training Allowance	\$80,167
Emergency Locum Service	\$200,000
Undergraduate Scholarship Internship Pharmacy - Student Placement	\$675,000
Undergraduate Pharmacy-Scholarship Scheme	\$1,200,000
CPE - Continuing Professional Education Allowance	\$300,777
Pharmacy - Rural Administration Support	\$470,000
Rural Pharmacy - Mentor Scheme	\$50,000
Post Intern Incentive Allowance	\$260,000
Undergraduate Scholarship Internship - Intern Incentive Allowance	\$600,000
RPLO	\$780,000
Program Total	\$4,615,944

Medication Management services consist of the following elements:	Actual Expenditure
Diabetes Medscheck and Medscheck	\$26,916,666
Residential Medication Management Review (RMMR)	\$13,333,332
Home Medicines Review (HMR)	\$14,732,117
Clinical Interventions by pharmacists (Pharmacy Practice Incentives)	\$16,500,000
Program Total	\$71,482,115

Medication Adherence services consist of the following elements:	Actual Expenditure
Dose Administration Aids (Pharmacy Practice Incentives)	\$70,637,433
Staged Supply (Pharmacy Practice Incentives)	\$7,916,666
Program Total	\$78,554,099

Aboriginal & Torres Strait Islander Programs consist of the following elements:	Actual Expenditure
Workforce (scholarships)	\$180,000
Workforce (traineeships)	\$160,000
Supporting s100 Remote Aboriginal Area Health Services (RAAHS)	\$2,748,750
Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander people (QUMAX)	\$2,529,958
Program Total	\$5,618,708

Table 19: Actual Costs of Major Components of CPA*, 2017-18

Component	Expenditure
Pharmacy remuneration	\$ 2,598,494,464
Wholesale remuneration	\$ 387,773,723
Professional programmes	\$ 182,019,950
Community Services Obligation (CSO)	\$ 195,220,000
Total	\$ 3,363,508,137

* The current Community Pharmacy Agreement is the 6th CPA.

NOTES:

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.
2. Professional programmes and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.
3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Health receives from Human Services. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

Table 20: Community Services Obligation (CSO) Expenditure, 2017-18

Component	Expenditure
CSO funding pool	\$ 193,931,345
CSO admin	\$ 1,288,655
Total	\$ 195,220,000

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health.

PBS Information Line Report, 2017-18

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1st July 2017 – 30th June 2018, the information line received **6,533** calls. This was a decrease of 11.70% from the previous financial year, where 7,399 calls were received.

A breakdown of calls by issue is not available due to changes in data capture during the period.

Breakdown of calls by month:

Month	Number of calls	%
July 2017	594	9.09%
August 2017	637	9.75%
September 2017	574	8.79%
October 2017	584	8.94%
November 2017	604	9.25%
December 2017	443	6.78%
January 2018	582	8.91%
February 2018	582	8.91%
March 2018	477	7.30%
April 2018	507	7.76%
May 2018*	457	6.99%
June 2018	492	7.53%
Total	6,533	100.00%

*No data was obtained for 29-30 May 2018 due to technical outages.

National Diabetes Services Scheme (NDSS)

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government. The current agreement runs from 1 July 2016 until 30 June 2020.

The NDSS is managed by the Department of Health through the Diabetes Products Section, in the Pharmacy Branch of the Technology Assessment and Access Division.

The NDSS provides registrants with access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin infusion pump consumables, and blood and urine testing strips, and are available through Access Points nationally. Access Points comprise community pharmacies and very small numbers of other entities, such as health centres, hospitals and aged care facilities. Since 1 April 2017, the NDSS has also provided fully subsidised continuous glucose monitoring products to eligible young Australians with Type 1 Diabetes, up to the age of 21 years.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%
2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%
2016-17	396,460	3.4%	859,610	3.8%	1,256,070	3.7%
2017-18	403,307	1.7%	873,632	1.6%	1,276,939	1.7%

National Diabetes Services Scheme Expenditure

Total NDSS expenditure for products for the 2017-18 financial year was \$205 million. From 2016-17, NDSS Registrant co-payments are now returned to Consolidated Revenue.

PBS Expenditure and Prescriptions 2017-18

Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2017-18)

PRESCRIPTIONS	GENERAL	PENSIONER	CONC	S/NET	TOTAL	DRS BAG	TOTAL - ALL PRESCRIPTIONS
1948/49	280,719				280,719		280,719
1949/50	484,210				484,210		484,210
1950/51	3,758,622				3,758,622		3,758,622
1951/52	6,515,668	1,655,570			8,171,238		8,171,238
1952/53	6,853,937	2,766,947			9,620,884		9,620,884
1953/54	7,004,421	3,453,551			10,457,972		10,457,972
1954/55	9,201,387	4,418,633			13,620,020		13,620,020
1955/56	8,970,890	5,235,013			14,205,903		14,205,903
1956/57	9,045,439	5,580,946			14,626,385		14,626,385
1957/58	10,309,446	6,313,214			16,622,660		16,622,660
1958/59	13,253,168	6,821,578			20,074,746		20,074,746
1959/60	16,624,342	8,028,968			24,653,310		24,653,310
1960/61	20,489,065	10,727,570			31,216,635		31,216,635
1961/62	26,050,370	11,664,036			37,714,406		37,714,406
1962/63	29,517,810	12,674,230			42,192,040		42,192,040
1963/64	31,039,624	13,317,273			44,356,897		44,356,897
1964/65	33,714,429	13,841,372			47,555,801		47,555,801
1965/66	35,084,551	14,908,393			49,992,944		49,992,944
1966/67	36,750,907	16,936,435			53,687,342		53,687,342
1967/68	37,053,212	18,369,634			55,422,846		55,422,846
1968/69	40,453,366	19,954,471			60,407,837		60,407,837
1969/70	44,071,198	21,504,166			65,575,364		65,575,364
1970/71	48,971,406	22,515,117			71,486,523		71,486,523
1971/72	48,491,692	23,950,503			72,442,195		72,442,195
1972/73	49,115,497	25,560,576			74,676,073		74,676,073
1973/74	59,499,823	27,788,036			87,287,859		87,287,859
1974/75	67,350,637	30,323,662			97,674,299		97,674,299
1975/76	67,722,534	33,394,757			101,117,291		101,117,291
1976/77	56,099,277	33,606,128			89,705,405		89,705,405
1977/78	57,751,904	35,414,619			93,166,523		93,166,523
1978/79	53,553,036	39,409,489			92,962,525		92,962,525
1979/80	46,624,224	42,450,386			89,074,610		89,074,610
1980/81	47,619,120	46,778,057			94,397,177		94,397,177
1981/82	53,834,648	49,739,756			103,574,404		103,574,404
1982/83	50,078,929	52,529,929	2,931,462		105,540,320		105,540,320
1983/84	41,938,964	56,491,285	9,954,995		108,385,244		108,385,244
1984/85	50,690,275	60,069,806	10,068,817		120,828,898		120,828,898
1985/86	46,334,279	63,191,858	10,315,799		119,841,936		119,841,936
1986/87	28,762,909	64,243,148	9,755,680	2	102,761,737		102,761,737
1987/88	12,339,360	81,041,242	7,520,752	15,059,811	100,901,354		100,901,354
1988/89	14,078,934	78,283,599	8,223,231	11,925,271	100,585,764		100,585,764
1989/90	15,361,517	80,761,310	8,856,241	11,725,474	104,979,068		104,979,068
1990/91	10,608,974	36,868,817	36,588,405	11,675,164	95,741,360	558,899	96,300,259

Notes
 -Dr's Bag prior to 90/91 included in General, from 90/91 included in miscellaneous expenditure
 -For 90/91 Concessional includes 'old' (prior to 1/11/90) prescriptions and 'new' (post 1/11/90) concessional category

Safety Net
 Prior to 90/91 S/net for Gen & Concess is included in pensioner. In 90/91 free s/net is in both pensioner and s/net categories

PBS Expenditure and Prescriptions 2017-18

Table 21(a): Historical Pharmaceutical Benefits Scheme Prescriptions (1948-49 to 2017-18) Continued

PRESCRIPTIONS	GENERAL			CONCESSIONAL			TOTAL PRESCRIPTIONS	DRS BAG	TOTAL- ALL PRESCRIPTIONS	
	NSN	S/Net 1	S/NET 2	TOTAL	NSN	S/NET				TOTAL
1991/92	8,266,835	2,340,145	1,092,314	11,699,294	67,331,793	14,428,608	81,760,401	93,459,695	660,459	94,120,154
1992/93	10,260,426	3,917,022	2,800,496	16,977,944	71,756,325	16,757,840	88,514,165	105,492,109	689,508	106,181,617
1993/94	11,451,148	4,259,245	3,087,943	18,798,336	77,536,126	18,003,354	95,539,480	114,337,816	704,227	115,042,043
1994/95	13,491,364	4,695,314	2,072	18,188,750	82,400,588	17,457,008	99,857,596	118,046,346	674,331	118,720,677
1995/96	14,212,731	5,488,957	52	19,701,740	85,604,215	18,898,907	104,503,122	124,204,862	683,420	124,888,282
1996/97	14,709,601	3,082,843	14	17,792,458	85,965,797	19,676,007	105,641,804	123,434,262	665,301	124,099,563
1997/98	14,087,393	3,945,591	17	18,033,001	86,389,807	20,060,505	106,450,312	124,483,313	628,496	125,111,809
1998/99	15,153,975	4,111,091		19,265,066	88,475,327	20,608,073	109,083,400	128,348,466	572,753	128,921,219
1999/00	16,296,703	3,928,760		20,225,463	94,281,872	23,078,282	117,360,154	137,585,617	496,306	138,081,923
2000/01	18,526,141	4,340,364		22,866,505	99,285,160	25,420,114	124,705,274	147,571,779	478,999	148,050,778
2001/02	19,292,104	4,813,038		24,105,142	102,018,211	28,406,603	130,424,814	154,529,956	448,283	154,978,239
2002/03	20,694,131	5,188,492		25,882,623	101,459,056	31,177,491	132,636,547	158,519,170	437,516	158,956,686
2003/04	22,443,338	5,544,618		27,987,956	104,619,866	32,827,303	137,447,169	165,435,125	426,976	165,862,101
2004/05	22,194,451	6,209,302		28,403,753	105,377,946	36,095,311	141,473,257	169,877,010	402,492	170,279,502
2005/06	20,917,523	5,910,828		26,828,351	105,152,486	35,945,690	141,098,176	167,926,527	396,088	168,322,615
2006/07	19,871,669	4,710,422		24,582,091	110,917,202	32,675,864	143,593,066	168,175,157	360,362	168,535,519
2007/08	19,607,454	4,553,340		24,160,794	113,118,234	33,680,813	146,799,047	170,959,841	336,182	171,296,023
2008-09	20,746,777	5,580,636		26,327,413	119,906,347	35,234,371	155,140,718	181,468,131	367,996	181,836,127
2009-10	21,226,750	4,763,435		25,990,185	122,832,364	34,756,644	157,589,008	183,579,193	332,344	183,911,537
2010-11	21,032,398	4,943,233		25,975,631	125,446,923	36,381,986	161,828,909	187,804,540	337,715	188,142,255
2011-12	21,239,413	4,820,643		26,060,056	130,441,952	38,046,697	168,488,649	194,548,705	324,424	194,873,129
2012-13	19,323,589	4,371,046		23,694,635	133,646,630	39,611,994	173,258,624	196,953,259	352,123	197,305,382
2013-14	18,050,307	4,052,529		22,102,836	145,340,393	42,009,011	187,349,404	209,452,240	363,763	209,816,003
2014-15	15,902,515	3,544,902		19,447,417	147,979,717	44,277,679	192,257,396	211,704,813	380,376	212,085,189
2015-16	13,770,978	3,180,897		16,951,875	146,529,394	44,119,861	190,649,255	207,601,130	388,859	207,989,989

New Series	GENERAL			CONCESSIONAL			TOTAL PBS	DRS BAG	MISC and S100	TOTAL - ALL PRESCRIPTIONS
	NSN	S/Net	TOTAL	NSN	S/Net	TOTAL				
2016-17	12,334,542	2,699,345	15,033,887	144,336,986	36,045,418	180,382,404	195,416,291	394,352	2,560,813	198,371,456
2017-18	13,332,423	2,616,813	15,949,236	148,018,925	37,047,645	185,066,570	201,015,806	398,051	2,645,790	204,059,647

CONC: Concessional

S/NET: Safety Net

PENSIONER: Before 1 November 1990 pensioners received PBS drugs free of charge.

NSN: Non Safety Net

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

MISC and SECT 100: Section 100 programmes.

Note: From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, prescriptions were reported by the date that they were processed by the Department of Human Services.

PBS Expenditure and Prescriptions 2017-18

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2017-18)

YEAR	GOVERNMENT EXPENDITURE - \$-					SUB TOTAL	HOSP & MISC		TOTAL GOVT COST	PATIENT CONTRIBUTION			TOTAL COST PRESCRIPTIONS	TOTAL with S.100 & Misc
	GEN	CONC	PENS	SAFETY NET						GEN	CON	TOTAL		
1948/49	132,536					132,536	165,538	298,074				-	132,536	298,074
1949/50	346,682					346,682	262,696	609,378				-	346,682	609,378
1950/51	5,453,558					5,453,558	406,768	5,860,326				-	5,453,558	5,860,326
1951/52	13,424,294		715,264			14,139,558	1,230,536	15,370,094				-	14,139,558	15,370,094
1952/53	12,399,568		1,457,316			13,856,884	573,734	14,430,618				-	13,856,884	14,430,618
1953/54	14,320,372		2,021,560			16,341,932	2,116,894	18,458,826				-	16,341,932	18,458,826
1954/55	16,303,940		2,589,672			18,893,612	2,585,322	21,478,934				-	18,893,612	21,478,934
1955/56	18,061,092		3,015,920			21,077,012	2,697,858	23,774,870				-	21,077,012	23,774,870
1956/57	17,171,670		3,586,200			20,757,870	2,675,776	23,433,646				-	20,757,870	23,433,646
1957/58	22,826,484		4,246,490			27,072,974	2,995,004	30,067,978				-	27,072,974	30,067,978
1958/59	33,112,570		5,034,746			38,147,316	3,798,278	41,945,594				-	38,147,316	41,945,594
1959/60	36,714,806		7,148,446			43,863,252	4,808,090	48,671,342	1,890,756		1,890,756	-	45,754,008	50,562,098
1960/61	34,282,496		14,676,698			48,959,194	6,803,248	55,762,442	10,324,740		10,324,740	-	59,283,934	66,087,182
1961/62	44,632,488		18,194,996			62,827,484	7,552,282	70,379,766	13,007,776		13,007,776	-	75,835,260	83,387,542
1962/63	47,093,026		19,830,750			66,923,776	9,986,382	76,910,158	14,742,448		14,742,448	-	81,666,224	91,652,606
1963/64	46,460,998		20,601,714			67,062,712	11,775,958	78,838,670	15,573,804		15,573,804	-	82,636,516	94,412,474
1964/65	48,929,748		21,564,420			70,494,168	11,708,442	82,202,610	16,841,354		16,841,354	-	87,335,522	99,043,964
1965/66	53,078,046		24,071,127			77,149,173	14,634,501	91,783,674	17,481,228		17,481,228	-	94,630,401	109,264,902
1966/67	56,655,939		29,280,268			85,936,207	15,344,592	101,280,799	18,347,036		18,347,036	-	104,283,243	119,627,835
1967/68	56,800,249		32,115,335			88,915,584	16,218,859	105,134,443	18,504,345		18,504,345	-	107,419,929	123,638,788
1968/69	64,024,983		36,609,257			100,634,240	17,739,118	118,373,358	20,129,402		20,129,402	-	120,763,642	138,502,760
1969/70	73,227,887		41,068,702			114,296,589	22,421,727	136,718,316	21,941,691		21,941,691	-	136,238,280	158,660,007
1970/71	88,176,385		45,180,856			133,357,241	26,917,666	160,274,907	24,384,028		24,384,028	-	157,741,269	184,658,935
1971/72	90,061,869		52,005,350			142,067,219	31,201,229	173,268,448	35,466,642		35,466,642	-	177,533,861	208,735,090
1972/73	87,431,438		58,139,459			145,570,897	32,061,691	177,632,588	48,640,243		48,640,243	-	194,211,140	226,272,831
1973/74	108,066,351		66,802,821			174,869,172	43,426,672	218,295,844	59,015,335		59,015,335	-	233,884,507	277,311,179
1974/75	131,341,320		80,586,986			211,928,306	50,368,781	262,297,087	66,827,982		66,827,982	-	278,756,288	329,125,069
1975/76	149,033,245		107,317,318			256,350,563	27,490,706	283,841,269	95,244,660		95,244,660	-	351,595,223	379,085,929
1976/77	111,077,507		115,201,775			226,279,282	8,623,582	234,902,864	111,676,421		111,676,421	-	337,955,703	346,579,285
1977/78	118,303,375		127,911,837			246,215,212	9,832,410	256,047,622	115,025,169		115,025,169	-	361,240,381	371,072,791
1978/79	110,425,438		151,125,681			261,551,119	9,767,502	271,318,621	129,540,759		129,540,759	-	391,091,878	400,859,380
1979/80	101,185,503		166,361,113			267,546,616	7,088,452	274,635,068	123,418,168		123,418,168	-	390,964,784	398,053,236
1980/81	107,903,558		191,043,798			298,947,356	10,267,063	309,214,419	129,923,272		129,923,272	-	428,870,628	439,137,691
1981/82	139,547,856		239,894,493			379,442,349	11,377,241	390,819,590	157,957,635		157,957,635	-	537,399,984	548,777,225
1982/83	131,773,044	11,100,973	272,707,495			415,581,512	14,685,428	430,266,940	170,617,530	5,882,844	176,500,374	-	592,081,886	606,767,314
1983/84	114,638,367	39,276,732	317,819,660			471,734,759	17,490,165	489,224,924	166,043,447	19,975,026	186,018,473	-	657,753,232	675,243,397
1984/85	142,439,672	43,266,712	356,213,948			541,920,332	17,877,162	559,797,494	201,142,242	20,208,116	221,350,358	-	763,270,690	781,147,852
1985/86	138,365,148	50,172,930	408,026,507			596,564,585	19,258,116	615,822,701	222,286,396	20,715,057	243,001,453	-	839,566,038	858,824,154
1986/87	140,571,611	59,738,152	514,236,037	12		714,545,800	23,457,302	738,003,102	167,130,307	22,048,299	189,178,606	-	903,724,406	927,181,708
1987/88	111,740,361	51,574,897	747,536,316	159,418,168		910,851,574	35,612,019	946,463,593	117,938,301	18,839,286	136,777,587	-	1,047,629,161	1,083,241,180
1988/89	132,040,607	63,272,252	795,027,196	138,531,290		990,340,055	33,194,842	1,023,534,897	147,704,171	20,603,194	168,307,365	-	1,158,647,420	1,191,842,262
1989/90	170,039,203	74,757,555	890,753,297	150,064,548		1,135,550,055	43,852,385	1,179,402,440	162,587,554	22,174,539	184,762,093	-	1,320,312,148	1,364,164,533
1990/91	157,783,001	342,720,328	428,743,821	580,709,870		1,094,463,443	64,798,247	1,159,261,690	132,120,868	91,672,986	223,793,854	-	1,318,257,297	1,383,055,544

Note -Free Pensioner category removed from 1 Nov 90, \$2.50 copayment and free safety net introduced for all Concessionals
 -Dr's Bag prior to 90/91 included in General from 90/91 (\$12,255,895) included in Misc

Safety Net -For Gen & Conc prior to 90/91 is included in Pensioner
 -For 90/91 S/net includes both pre & post 1/11/90 free Snet
 -Gen S/net 1 included in Concess in 90/91
 -Gen S/net 2 (free) 1 Jan 91 to 31 Dec 93

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2017-18) Continued

GOVERNMENT EXPENDITURE - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
1991/92	160,765,548	36,400,482	18,911,584	216,077,614	708,413,833	195,000,082	903,413,915	1,119,491,529	100,877,826	1,220,369,355	
1992/93	188,270,160	65,845,466	53,077,875	307,193,500	844,972,301	251,249,539	1,096,221,840	1,403,415,340	101,552,426	1,504,967,766	
1993/94	224,675,364	78,832,510	63,861,452	367,369,326	1,019,651,580	297,597,894	1,317,249,474	1,684,618,800	116,696,888	1,801,315,688	
1994/95	290,765,883	93,406,668	38,565	384,211,116	1,194,999,580	302,502,892	1,497,502,472	1,881,713,588	109,621,215	1,991,334,803	
1995/96	343,025,066	118,655,085	785	461,680,936	1,369,432,585	360,130,508	1,729,563,093	2,191,244,029	135,473,133	2,326,717,162	
1996/97	392,246,135	72,831,781	210	465,078,126	1,465,657,637	401,814,359	1,867,471,996	2,332,550,122	205,545,012	2,538,095,134	
1997/98	411,856,192	98,613,376	465	510,470,033	1,576,058,096	439,989,321	2,016,047,417	2,526,517,450	258,950,240	2,785,467,690	
1998/99	469,042,094	106,618,491	-	575,660,585	1,739,535,268	467,079,112	2,206,614,380	2,782,274,965	287,469,135	3,069,744,100	
1999/00	521,018,128	107,012,848	-	628,030,976	2,000,636,597	547,829,734	2,548,466,331	3,176,497,307	311,727,262	3,488,224,569	
2000/01	662,099,200	128,173,886	-	790,273,086	2,359,650,038	660,303,947	3,019,953,985	3,810,227,071	347,901,802	4,158,128,873	
2001/02	691,204,687	148,498,520	-	839,703,207	2,569,555,585	778,411,796	3,347,967,381	4,187,670,588	396,386,682	4,584,057,270	
PATIENT CONTRIBUTION - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
1991/92	128,988,053	6,043,066	-	135,031,119	173,201,117	-	173,201,117	308,232,236	1,427,723,765	100,877,826	1,528,601,591
1992/93	162,967,769	10,202,578	-	173,170,347	186,726,902	-	186,726,902	359,897,249	1,763,312,589	101,552,426	1,864,865,015
1993/94	183,012,475	11,074,025	-	194,086,500	201,596,301	-	201,596,301	395,682,801	2,080,301,601	116,696,888	2,196,998,489
1994/95	218,094,751	12,207,816	-	230,302,567	214,241,512	-	214,241,512	444,544,079	2,326,257,667	109,621,215	2,435,878,882
1995/96	237,239,817	14,278,699	-	251,518,516	226,583,554	-	226,583,554	478,102,070	2,669,346,099	135,473,133	2,804,819,232
1996/97	269,715,066	8,375,980	-	278,091,046	252,104,590	-	252,104,590	530,195,636	2,862,745,758	205,545,012	3,068,290,770
1997/98	281,739,252	12,625,016	-	294,364,268	276,440,026	-	276,440,026	570,804,294	3,097,321,744	258,950,240	3,356,271,984
1998/99	305,064,052	13,155,417	-	318,219,469	283,117,963	-	283,117,963	601,337,432	3,383,612,397	287,469,135	3,671,081,532
1999/00	333,003,549	12,584,337	-	345,587,886	306,183,001	-	306,183,001	651,770,887	3,828,268,194	311,727,262	4,139,995,456
2000/01	392,432,536	14,353,837	-	406,786,373	337,379,028	-	337,379,028	744,165,401	4,554,392,472	347,901,802	4,902,294,274
2001/02	426,974,621	16,864,336	-	443,838,957	362,237,529	-	362,237,529	806,076,486	4,993,747,074	396,386,682	5,390,133,756
DOCTOR'S BAG - \$ - (included in miscellaneous from 90/91)											
1990/91	12,255,895	-	-	-	-	-	-	-	-	-	-
1991/92	14,514,725	-	-	-	-	-	-	-	-	-	-
1992/93	16,082,655	-	-	-	-	-	-	-	-	-	-
1993/94	16,679,933	-	-	-	-	-	-	-	-	-	-
1994/95	15,674,643	-	-	-	-	-	-	-	-	-	-
1995/96	16,202,098	-	-	-	-	-	-	-	-	-	-
1996/97	15,769,173	-	-	-	-	-	-	-	-	-	-
1997/98	14,953,823	-	-	-	-	-	-	-	-	-	-
1998/99	13,370,491	-	-	-	-	-	-	-	-	-	-
1999/00	10,754,395	-	-	-	-	-	-	-	-	-	-
2000/01	10,343,534	-	-	-	-	-	-	-	-	-	-
2001/02	9,803,682	-	-	-	-	-	-	-	-	-	-

note- from 91/92 all figures are sourced from Department of Human Services (DHS) processing where available
-miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.
CONC: Concessional
S/Net: Safety Net
GEN: General
NSN: Non Safety Net
MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.
HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.
PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Historical Pharmaceutical Benefits Scheme Expenditure (1948-49 to 2017-18) Continued

PBS Expenditure and Prescriptions 2017-18

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2002/03	\$747,049,026	\$169,693,390	\$916,742,416	\$2,741,874,040	\$907,119,434	\$3,648,993,474	\$4,565,735,890	\$477,352,298	\$5,043,088,188	
2003/04	\$824,130,608	\$190,682,979	\$1,014,813,587	\$2,972,331,634	\$1,004,522,779	\$3,976,854,413	\$4,991,668,000	\$570,500,000	\$5,562,168,000	
2004/05	\$850,690,906	\$222,668,220	\$1,073,359,125	\$3,077,033,801	\$1,145,497,231	\$4,222,531,032	\$5,295,890,157	\$668,500,000	\$5,964,390,157	
2005/06	\$850,095,680	\$216,246,563	\$1,066,342,242	\$3,145,480,431	\$1,172,502,111	\$4,317,982,542	\$5,384,324,784	\$764,000,000	\$6,148,324,784	
2006/07	\$890,275,536	\$174,127,771	\$1,064,403,307	\$3,333,875,949	\$1,067,478,074	\$4,401,354,023	\$5,465,757,330	\$886,500,000	\$6,352,257,330	
2007/08	\$1,039,451,749	\$173,499,550	\$1,212,951,299	\$3,561,294,283	\$1,137,925,393	\$4,699,219,676	\$5,912,170,974	\$975,500,000	\$6,887,670,974	
2008/09	\$1,220,279,806	\$217,487,483	\$1,437,767,290	\$3,909,584,010	\$1,216,050,241	\$5,125,634,250	\$6,563,401,540	\$1,081,400,000	\$7,644,801,540	
2009/10	\$1,339,182,210	\$199,599,002	\$1,538,781,212	\$4,220,391,341	\$1,259,719,602	\$5,480,110,943	\$7,018,892,155	\$1,232,400,000	\$8,251,292,155	
2010-11	\$1,412,781,352	\$211,944,918	\$1,624,726,270	\$4,367,739,898	\$1,330,682,636	\$5,698,422,533	\$7,323,148,803	\$1,335,500,000	\$8,658,648,803	
2011-12	\$1,453,773,280	\$208,167,009	\$1,661,940,288	\$4,476,104,435	\$1,390,159,396	\$5,866,263,831	\$7,528,204,119	\$1,473,700,000	\$9,001,904,119	
2012-13	\$1,339,654,102	\$169,213,844	\$1,508,867,945	\$4,209,086,581	\$1,351,536,398	\$5,560,622,979	\$7,069,490,924	\$1,812,600,000	\$8,882,090,924	
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2002/03	\$470,306,937	\$18,698,099	\$489,005,036	\$370,426,183	-	\$370,426,183	\$859,431,219	\$5,425,167,109	\$477,352,298	\$5,902,519,407
2003/04	\$524,763,848	\$20,538,514	\$545,302,362	\$392,513,143	-	\$392,513,143	\$937,815,505	\$5,929,483,505	\$570,500,000	\$6,499,983,505
2004/05	\$572,963,103	\$23,742,733	\$596,705,836	\$443,930,641	-	\$443,930,641	\$1,040,636,477	\$6,336,526,634	\$668,500,000	\$7,005,026,634
2005/06	\$606,897,345	\$27,199,070	\$634,096,415	\$489,173,277	-	\$489,173,277	\$1,123,269,692	\$6,507,594,476	\$764,000,000	\$7,271,594,476
2006/07	\$596,483,266	\$22,154,622	\$618,637,888	\$532,682,972	-	\$532,682,972	\$1,151,320,859	\$6,617,078,189	\$886,500,000	\$7,503,578,189
2007/08	\$607,183,393	\$22,323,024	\$629,506,417	\$559,962,883	-	\$559,962,883	\$1,189,469,300	\$7,101,640,274	\$975,500,000	\$8,077,140,274
2008/09	\$663,449,571	\$27,928,829	\$691,378,400	\$617,378,323	-	\$617,378,323	\$1,308,756,723	\$7,872,158,263	\$1,081,400,000	\$8,953,558,263
2009/10	\$701,961,714	\$25,253,391	\$727,215,106	\$656,949,638	-	\$656,949,638	\$1,384,164,743	\$8,403,056,898	\$1,232,400,000	\$9,635,456,898
2010-11	\$707,968,006	\$26,706,262	\$734,674,267	\$689,108,592	-	\$689,108,592	\$1,423,782,860	\$8,746,931,663	\$1,335,500,000	\$10,082,431,663
2011-12	\$735,994,339	\$27,003,502	\$762,997,841	\$742,139,779	-	\$742,139,779	\$1,505,137,620	\$9,033,341,739	\$1,473,700,000	\$10,507,041,739
2012-13	\$689,036,554	\$25,352,649	\$714,389,203	\$781,002,893	-	\$781,002,893	\$1,495,392,096	\$8,564,883,021	\$1,812,600,000	\$10,377,483,021

Doctor's Bag - \$ - (included in miscellaneous from 90/91)

2002/03	\$9,510,606
2003/04	\$9,408,669
2004/05	\$9,365,803
2005/06	\$10,063,803
2006/07	\$10,698,205
2007/08	\$13,468,779
2008/09	\$14,533,302
2009/10	\$13,571,776
2010-11	\$14,228,520
2011-12	\$12,974,506
2012-13	\$14,755,085

note- from 91/92 all figures are sourced from Department of Human Services (DHS) processing where available -miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

Table 21(b): Pharmaceutical Benefits Scheme History - Government Expenditure & Patient Contribution, 1948-49 to 2017-18 Continued

GOVERNMENT EXPENDITURE - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2013-14	\$1,429,860,300	\$154,692,449	\$1,584,552,749	\$4,319,414,670	\$1,388,583,542	\$5,707,998,212	\$7,292,550,961	\$2,033,900,000	\$9,326,450,961	
2014-15	\$1,463,256,600	\$129,523,975	\$1,592,780,575	\$4,123,482,128	\$1,380,416,342	\$5,503,898,470	\$7,096,679,044	\$2,183,101,118	\$9,279,780,162	
2015-16	\$1,785,357,915	\$118,821,879	\$1,904,179,793	\$4,630,980,302	\$1,413,858,158	\$6,044,838,460	\$7,949,018,254	\$2,752,825,107	\$10,701,843,361	
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	DRS BAG	MISC and S100	TOTAL GOVT EXP
2016-17	\$2,088,188,915	\$103,984,977	\$2,192,173,892	\$5,315,606,905	\$1,204,716,252	\$6,520,323,157	\$8,712,497,049	\$16,718,674	\$3,043,936,194	\$11,773,151,917
2017-18	\$1,981,594,072	\$101,429,150	\$2,083,023,223	\$5,127,198,161	\$1,236,961,876	\$6,364,160,037	\$8,447,183,260	\$16,568,617	\$3,139,112,049	\$11,602,863,926
PATIENT CONTRIBUTION - \$-										
	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST TOTAL - FOR PRESCRIPTIONS	MISC and SECT 100	TOTAL
2013-14	\$656,913,329	\$23,915,012	\$680,828,341	\$864,226,399	-	\$864,226,399	\$1,545,054,740	\$8,837,605,701	\$2,033,900,000	\$10,871,505,701
2014-15	\$567,399,905	\$21,021,090	\$588,420,995	\$877,483,279	-	\$877,483,279	\$1,465,904,274	\$8,562,583,318	\$2,183,101,118	\$10,745,684,436
2015-16	\$494,124,051	\$19,115,443	\$513,239,494	\$880,965,644	-	\$880,965,644	\$1,394,205,138	\$9,343,223,391	\$2,752,825,107	\$12,096,048,498
New Series	GENERAL-NSN	GEN S/Net	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL PBS	TOTAL COST *	MISC and S100	TOTAL EXP **
2016-17	\$444,029,285	\$16,448,625	\$460,477,909	\$880,418,081	-	\$880,418,081	\$1,340,895,990	\$10,053,393,039	\$38,361,124	\$13,152,409,031
2017-18	\$484,120,874	\$16,143,997	\$500,264,871	\$915,055,636	-	\$915,055,636	\$1,415,320,507	\$9,862,503,767	\$40,183,135	\$13,058,367,568
TOTAL COST *	Total cost for Section 85 (Patient payment + government benefit)									
TOTAL EXP **	Total PBS Expenditure, Section 85, Section 100 and Drs Bag (Patient payment + government benefit)									
Doctor's Bag - \$ - (included in miscellaneous from 90/91)										
2013-14	\$16,009,408									
2014-15	\$16,340,036									
2015-16	\$15,887,150									
2016-17	\$16,718,674									
2017-18	\$16,568,617									

Notes:

From 2016-17, the data is reported by the date that a prescription was supplied. Prior to this, Government expenditure and patient contributions were reported by the date that the prescriptions were processed by the Department of Human Services.
 From 1991-92 all figures are sourced from Department of Human Services (DHS) processing where available
 Miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.

CONC: Concessional

S/Net: Safety Net

GEN: General

NSN: Non Safety Net

MISC and SECT 100: Section 100 programmes, other ungrouped expenditure

HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.

PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.